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CHAPTER I
INTRODUCTION AND LITERATURE REVIEW
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Thoracic Aortic Aneurysms and Dissections
An aneurysm is an enlargement or dilatation of an artery, and a dissection is a tear
partway through the aortic wall, creating a false lumen for blood flow. Aortic aneurysms and
dissections are the most common type of aortic disease and are a leading cause of death in
the U.S., affecting approximately 6 out of every 100,000 people and claiming approximately
16,000 lives each year (1;2). Aneurysms of the ascending aorta are defined as greater than or
equal to 1.5 times the size of the normal aorta (3). Aneurysms can occur anywhere along the
length of the aorta and are classified according to anatomical location. Thoracic aortic
aneurysms account for approximately 48% of all aneurysms (2). The natural progression of
aneurysms is to progressively enlarge over time until the vessel wall weakens and eventually
dissects. An aortic dissection can either be acute (diagnosed less than 2 weeks after the
dissection occurred) or chronic, and can occur as part of a spectrum of aortic disease even
without aneurysm formation (4). Dissections are most commonly classified using either the
Stanford system or the DeBakey system. According to the Stanford classification, Type A
dissections involve the ascending aorta, and may also involve the arch or descending aorta,
while Type B dissections involve only the descending aorta. According to the DeBakey
system, dissections are classified as Type I, Type II, or Type III. A Type I dissection
involves the entire length of the aorta, a Type II dissection includes only the ascending aorta,
and a Type III dissection includes only the descending aorta (5).
Aneurysms are generally asymptomatic until a catastrophic event i.e. a dissection
occurs. Some patients develop chronic heart failure as the aneurysm expands due to
distortion of the aortic valve and subsequent aortic valve insufficiency, but aneurysms
remain largely undetected until they either dissect or rupture (5). Symptoms of an aortic
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dissection, including sudden and severe chest pain, are similar to those of a myocardial
infarction and are initially misdiagnosed in up to 30% of cases, and this misdiagnosis can
prove to be deadly (5-7). Beta-adrenergic receptor blocking agents are currently used to
lower blood pressure in patients (8;9). However, while these drugs can slow the rate of
aneurysm growth, they do not prevent aortic disease from eventually progressing to
dissection (10). No drug treatment to prevent the underlying disease process exists. The only
available treatment option when the aorta continues to enlarge despite beta-blocker therapy
is surgical repair of the aorta once an aneurysm reaches a certain size or growth rate (5). A
dissection must be emergently repaired in order to prevent death, since the mortality rate
increases by 1% to 2% every hour after an acute dissection (9). Recommendations for
treatment are based on the size of the aneurysm, its location, and its rate of growth.
Individuals are generally referred for surgery when the aneurysm reaches a diameter of 5.56.0 cm for patients, or if the aneurysm grows more than 0.5 cm in 6 months as assessed by
serial MRI scans. For patients with a family history, surgery is recommended once the
aneurysm reaches a diameter between 4.5-5.0 cm. Surgical repair involves replacing the
aneurysmal portion of the aorta with a Dacron graft (5).
The aortic wall is composed of three major layers: the intima, media, and adventitia.
The intima is composed of one layer of endothelial cells. Although the endothelial layer in
small arteries is responsive to shear stress and is involved in regulation of vascular tone, it is
not clear whether the endothelium of large arteries, including the aorta, is involved in this
type of regulation. The medial layer is composed of smooth muscle cells and elastic fibers.
Elastic fibers are composed of elastin as well as fibulin and fibrillin-containing microfibrils,
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and enable the aorta to return to a normal size and shape after stretching due to pulsatile
blood flow (Figure I-1) (11).
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Figure I-1. Aortic wall structure. H&E and Movat staining of control (A,C) and aneurysmal
(B,D) aortic tissue, showing the three major layers of the aortic wall. Tissues are oriented
with the adventitial layer at the top of the image. In the Movat stains, elastic fibers are black,
cells are red, proteoglycans are blue, and collagens are yellow. In normal aortas (A,C), the
outer adventitial layer contains small blood vessels that supply nutrients to the aortic wall, a
4

medial layer composed of elastic fibers (black) and SMCs (red), and an intimal layer
composed of endothelial cells. SMCs and elastic fibers are arranged in concentric layers (E)
and are interconnected with contractile filaments in SMCs through focal adhesions (E,F). In
contrast, aneurysmal aortas (B,D) are characterized by areas of proteoglycan accumulation
(blue) and focal areas of SMCs loss. Adapted from (12).
**************************************************************************
Fibrillin-1 has both a structural role and a regulatory role within the vessel wall.
Fibrillin-1 binds to αvβ3, α5β1, and αvβ6 integrins on the surface of SMCs, contributing to
aortic wall structure (13). Additionally, fibrillin contains multiple latent TGF-β binding
protein (LTBP) domains and a specific fragment of fibrillin-1 is capable of releasing TGFβ1 from large latent complexes in the ECM, leading to TGF-β1 activation (Figure I-2) (14).

Figure I-2. Fibrillin-1 controls TGF-β1 activation. Fibrillin-1 has structural similarities to
and associates with large latent complexes containing LTBP-1, latency-associated peptide
(LAP), and TGF-β1. The small latent complex (SLC) is composed of TGF- β1 and LAP.
Breakdown in the structure of fibrillin-1 can lead to TGF- β1 activation through cleavage of
the latent complex and release of TGF-β1 peptide into the extracellular matrix. Adapted by
permission from Macmillan Publishers Ltd: [Nature Genetics] (15), copyright (2003).
5

**************************************************************************
Fibulin-4 and fibulin-5 play an essential role in assembly of elastic fibers within the vessel
wall, and loss of either of these proteins results in severe vascular defects (16;17). Elastin
deficiency in mice and humans results in excessive SMC proliferation and the development
of supravalvular aortic stenosis (SVAS), highlighting the importance of elastin in both
maintaining the structural integrity of the aorta and in maintaining SMCs in a quiescent,
contractile state (18). Elastic fibers and SMCs are arranged in concentric layers within the
aortic wall, with each layer of SMCs and its associated elastic fibers representing one
lamellar unit (Figure I-1E) (11).
The third major layer of the aorta is an outer adventitial layer containing
myofibroblasts, adipose tissue, small nerve endings, and vasa vasorum, small blood vessels
located close to the medial surface that supply nutrients to the vessel wall. Aneurysms are
characterized by medial degeneration, including loss and fragmentation of elastic fibers,
SMC loss, proteoglycan accumulation, and in some cases are accompanied by inflammation
(Figure I-1B,D) (19-21). Proteoglycan accumulation is one of the earliest pathologic
findings and has been found prior to aneurysm formation (22). Fragmentation of elastic
fibers is the most common feature and is found in >90% of aneurysms, while cystic medial
changes, SMC loss, atherosclerotic changes, and thickening of the vasa vasorum were found
in 70%, 45%, 41%, and 20% of ascending aneurysms (19). Numerous studies have shown
increased expression of multiple matrix metalloproteases (MMPs), which cause ECM
degradation and account for some of the pathologic changes observed in TAAD, particularly
elastic fiber degradation (23-25). These processes lead to weakening of the aortic wall,
leaving it more prone to dissect.
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In 1991, missense mutations in FBN1, encoding fibrillin-1, were found to cause
Marfan syndrome (MFS, OMIM no. 154700) (26). MFS is inherited in an autosomal
dominant manner, occurs in approximately 1 out of every 5,000 individuals, and leads to
TAAD as well as a number of pleiotropic effects including mitral valve prolapse, long bone
overgrowth, joint hypermobility, and ectopia lentis (27). FBN1 mutations result in altered
secretion and deposition of fibrillin-1 in the ECM (28). These studies provided the first
evidence that aortic aneurysms could be caused due to a single gene defect.
Approximately 20% of individuals with TAAD have one or more affected family
members, providing evidence of a genetic basis for nonsyndromic TAAD (29;30).
Aneurysms are inherited in these families in an autosomal dominant manner, and exhibit
variable ages of onset and decreased penetrance (4). In addition, these families show
variability in the associated cardiovascular complications associated with the thoracic aortic
disease, including bicuspid aortic valve, intracranial aneurysms and popliteal aneurysms (3).
So far, seven published loci have been linked to TAAD, and the putative genes at four of
these loci have been identified (20;31-34). Several additional mutations and/or loci have
been identified and are currently being further confirmed and characterized.
Mutations in TGFBR1 and TGFBR2, encoding for the transforming growth factor-β
type I and II receptors, respectively, have been identified as causes of familial TAAD
(32;35). These findings, along with studies of TGF-β1 signaling in other aneurysm
syndromes associated with TGFBR1 or TGFBR2 mutations, led to the hypothesis that
familial TAAD may be driven, at least in part, by dysregulation of TGF-β signaling (3).
However, mutations in TGFBR1 or TGFBR2 account for less than 5% of familial TAAD.
Furthermore, dysregulation of TGF-β signaling as a common mechanism driving TAAD is
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controversial. More recently, mutations in ACTA2 and MYH11 encoding for the smooth
muscle cell (SMC)-specific contractile proteins SM α-actin and myosin heavy chain (SMMHC), were found to cause TAAD (34;36). While MYH11 mutations account for <2% of
familial TAAD cases, ACTA2 mutations account for approximately 15% of familial TAAD
cases, making contractile gene mutations the most common cause of familial TAAD
(34;36). Subsequently, mutations in MLCK, encoding myosin light chain kinase, were
identified as a cause of familial TAAD (Wang et al, manuscript submitted).
Approximately 80% of TAAD cases occur in individuals with no known family
history of aortic disease. Sporadic aneurysms generally have a later age of onset than
familial aneurysms (30). The major causes remain unknown; however, the pathology
associated with the TAAD cases is highly similar. Regardless of the major causes of
sporadic TAAD, much insight can be gained from study of the pathogenesis of familial
TAAD and potentially applied to aid in management of sporadic patients also.
In addition to MFS and nonsyndromic familial TAAD, multiple genetically inherited
syndromes are associated with this spectrum of disease. Part of this spectrum of diseases
includes defined syndromes as well as nonsyndromic familial TAAD due to mutations in the
TGF-β receptors. Furlong et al. described a Marfan-like syndrome in 1987 characterized by
craniosynostosis and TAAD; however, the genetic mutation was not identified (37). LoeysDietz syndrome was characterized in 2005, was found to share similar characteristics with
Furlong syndrome, and was found to be caused by mutations in either the TGF-β type I or II
receptors (38). Subsequently, patients with the originally diagnosed Furlong syndrome were
also found to harbor TGFBR2 mutations (39). Mutations in these receptors also lead to
familial TAAD. In this subgroup of patients, major features of Loeys-Dietz syndrome are
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missing but aneurysms also present in arteries other than the aorta, particularly in patients
with TGFBR1 mutations (35).
Some degree of overlap exists in the aneurysm disease phenotypes caused by these
mutations. For example, TGFBR2 mutations have been shown to lead to multiple distinct
aneurysm disorders, including LDS, familial TAAD, and MFS (32;38;40). Unique features
found in LDS but not MFS or one other closely related syndrome include arterial tortuosity,
cleft palate, atrial septal defects, and patent ductus arteriosus; however, a patient with
Furlong/LDS was found to harbor an FBN1 mutation (38;39). Additionally, TGFBR2
mutations were found in a subset of patients with clinical features of Marfan syndrome (40).
An ongoing controversy exists over whether TGFBR2 in addition to FBN1 mutations result
in true cases of MFS (41). A more recent study of 547 probands showed that TGFBR1 and
TGFBR2 mutations cause LDS in 87.5% of cases, but also cause MFS or familial TAAD in
the remainder of the cases (42). The majority of the data indicate that these disorders
represent a spectrum of disease caused by multiple different mutations, rather than single,
isolated clinical entities. The presence of these overlaps in phenotype could have
implications for the clinical management of disease.
Vascular Ehlers-Danlos syndrome (EDS) represents another inherited genetic
syndrome associated with aneurysms, and is caused by mutations in the COL3A1 gene,
encoding type III procollagen (43). Individuals with vascular EDS have aneurysms,
dissections, and rupture of various arteries throughout the body but can also develop TAAD.
In addition, these individuals have thin, translucent skin, atrophic scars, and are predisposed
to bowel rupture, along with rupture of the gravid uterus. Repair of ascending aneurysms in
these individuals is difficult due to the fragility of the vessel tissue (43). Other disorders that
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also lead to TAAD in more rare cases include EDS associated with filamin A mutations,
tuberous sclerosis caused by TSC2 mutations, Turner syndrome, osteogenesis imperfecta,
Alagille syndrome, and adult polycystic kidney disease (44-48).
Additional factors contributing to the development of TAAD include genetic
polymorphisms and environmental risk factors. A polymorphism in the MMP9 gene is
associated with TAAD (49). Hypertension and environmental factors, including
weightlifting, can also both induce aneurysm formation and aggravate aneurysm phenotypes
in individuals who are already genetically predisposed to TAAD (12).
In summary, TAAD represents a spectrum of disease exhibiting both genetic and
phenotypic heterogeneity, as well as overlap among some of the specific defined syndromes.
Although much has been done to advance the field in terms of improving surgical
techniques and outcomes and identifying novel mutations leading to disease, the precise
mechanisms leading to medial degeneration and expansion of the vessel wall are still not
completely understood, and viable non-surgical treatment options for this spectrum of
disease are lacking.

SMC Biology and Blood Vessel Biology
An understanding of the structure and function of SMCs and arteries is essential for
gaining insight into the pathogenesis of TAAD. Vascular SMCs arise from multiple different
origins during development, and a summary of these origins is shown in Figure I-3.
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Figure I-3. Diverse developmental origins of vascular SMCs. Vascular SMCs arise from
multiple embryonic origins, and are color coded accordingly. Reprinted by permission from
Wolters Kluwer Health (50), copyright (2007).
**************************************************************************
For example, SMCs in the ascending aorta as well as the carotid arteries arise from neural
crest cells, while SMCs in the descending aorta are mesenchymal derived (50). Treatment of
neural crest derived vs. mesenchymal derived cells with TGF-β1 results in different cellular
responses, suggesting that these cells are functionally similar but not completely identical
(51).
In contrast to skeletal and cardiac myocytes, which are terminally differentiated,
SMCs are able to switch between a quiescent, contractile phenotype and a proliferative,
synthetic phenotype (52;53). SMC phenotypic plasticity is closely tied with contractile
function and response to external stimuli including stretch (54). Differentiated SMCs are
generally quiescent and non-proliferative, and are characterized by prominent stress fibers
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and high expression of contractile proteins including SM α-actin, smooth muscle β-myosin,
calponin, smoothelin, SM22, and tropomyosins (54;55). Dedifferentiated SMCs have a more
synthetic phenotype characterized by increased amounts of rough endoplasmic reticulum
and large Golgi complexes, decreased contractile protein expression, more production of
ECM proteins, and increased proliferation and migration (55). These two phenotypes are not
necessarily mutually exclusive of one another, however (56).
Phenotypic switching to a more de-differentiated state allows SMCs to repair the
vessel wall after injury. However, in disease states an overabundance of this response proves
to be detrimental (54). SMC phenotypic modulation plays an important role in vascular
proliferative diseases including atherosclerosis and restenosis of vascular stent grafts (57).
Dedifferentiated SMCs are also found in aneurysms (22). Regulation of SMC phenotype is
highly complex, is mediated by a variety of extracellular signals, and is transcriptionally
regulated through multiple different pathways. Serum response factor (SRF) acts as a
molecular switch, regulating either a contractile phenotype or a proliferative phenotype,
dependent on its binding to either the myocardin family of transcription factors to promote
SMC gene expression, or ternary complex factors (TCFs), to promote expression of
proliferative genes (58). Multiple cytokines and growth factors also contribute to SMC
phenotypic modulation. PDGF-β is known to potent stimulator of SMC proliferation and
migration, while TGF-β1 has been known to promote either differentiation or proliferation
depending on the concentration used (51;54).
The proper contractile function of differentiated SMCs is essential for maintaining
structural integrity within the vascular wall. SMCs differ from cardiac and skeletal muscle in
that they lack sarcomeres, but the sliding filament mechanism of contraction in SMCs is
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similar to the mechanism in striated muscle cells, and provides a means of generating
contractile force (59;60). Multiple proteins are involved in the regulation of SMC actinmyosin crossbridge cycling, including tropomyosin, calponin, and caldesmon: actin and
myosin are the major focus of this study. Myosin consists of two heavy chains, two
essential light chains, and two regulatory light chains. Each myosin heavy chain is
composed of a globular head domain that has ATPase activity, and an α-helical coiled-coil
region (61). ATP exchange causes release of myosin from actin filaments, along with a
conformational change in the myosin head domain (Figure I-4A,B).

Figure I-4. Myosin crossbridge cycling. ATP exchange and hydrolysis results in a “power
stroke” that results in shortening of actin and myosin filaments and subsequent muscle
contraction. From (62). Reprinted by permission from AAAS.
**************************************************************************
Binding of actin to myosin accelerates the rate of ATP hydrolysis. Subsequent release of the
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phosphate causes in another conformational change in myosin, pulling on the filaments and
resulting in muscle shortening (Figure I-4C-E) (61).
In contrast to the structure of skeletal and cardiac myocytes, where filaments are
bundled together in a distinct pattern into myofibrils, contractile filaments in SMCs are
distributed in a nonuniform manner, and can adapt their length and organization in response
to stimuli (60;63). Additionally, SMCs are thought to bundle and act together in a
mechanical syncytium rather than as single cells contracting individually, allowing for force
to be distributed uniformly among the cells (60). In this model, contractile filaments are
attached to the cell membrane at dense plaques, which are structures homologous to the
focal adhesions (FA) observed in other cell types (60;64). FAs form a critical link between
the ECM and contractile elements in the cell, creating a continuum along which mechanical
force signals can be transduced, and also regulate intracellular signaling (65;66). Focal
adhesion kinase (FAK) is a critical part of the FA complex, acting as a mechanosensor, a
scaffold for recruitment of other proteins to these complexes, and a regulator of FA turnover
(67;68). In FAK-deficient SMCs, Ca2+ signaling and cellular contractility in response to
acetylcholine and KCl are disrupted, demonstrating the importance of intact FAK activation
for proper SMC contractile function (69). Overall, FAs play an essential role in both
regulating tension development and SMC contractility and mediating cell signaling events;
however, specific roles of FAs in TAAD pathogenesis have not yet been described.
As stated previously, SMCs are arranged in concentric layers between elastic
lamellae in the aortic wall (70). Large arteries have a high elastin content and are able to
withstand higher pressures from blood flow than smaller arteries. The high elastin content
promotes a differentiated SMC phenotype, and has an inhibitory effect on SMC proliferation
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(57). In contrast, smaller arteries are subjected to less pressure from blood flow and are more
muscular in structure, containing an internal and external elastic lamina, but no elastic
lamellae. Small arteries are also prone to excessive SMC dedifferentiation, proliferation, and
migration in response to injury. Numerous studies have shown that carotid artery injury
causes SMC proliferation and migration, leading to formation of a neointimal layer of SMCs
and ultimately to vessel occlusion (71-73).

Current Understanding of TAAD Pathogenesis
Multiple diverse pathways contribute to TAAD pathogenesis, and some insight has
been gained both from the study of TAAD as well as abdominal aortic aneurysms. Some of
the major pathways and processes identified include TGF-β1 signaling, SMC phenotypic
switching, increased MMP expression, and more recently, SMC contractile dysfunction.
Most of the current TAAD research is focused on the role of TGF-β signaling in the
disease process. This is partly owing to the fact that the Fbn1 underexpressing and Fbn1
mutant mice were the first mouse models developed to understand the pathogenesis of MFS,
and more broadly, TAAD. These models have suggested a role for TGF-β signaling in
aneurysm formation in Marfan syndrome (10). Increased phospho-Smad2, an indicator of
TGF-β1 signaling, was found in aortas of patients with LDS (38). This increase is
paradoxical because the mutations in TGFBR1 and TGFBR2 are all located in the
intracellular kinase domain and are predicted to result in decreased kinase function, thereby
disrupting TGF-β signaling (38). Losartan, an angiotensin II receptor antagonist, prevents
Smad2 phosphorylation, medial degeneration, and aneurysm formation in the MFS mouse
model (10). Clinical trials are underway to determine whether Losartan delays disease
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progression in individuals with MFS (74). However, no established treatment currently
exists for directly delaying and/or preventing aneurysm formation either in individuals with
MFS, or with other syndromic or nonsyndromic conditions that predispose to aneurysm
formation.
Some controversy exists as to whether TGF-β1 signaling represents a common
pathway leading to familial TAAD. SMCs from familial TAAD patients without identified
mutations show a common dysregulation of stretch-induced signaling pathways (Lafont et
al, manuscript submitted). Mutations leading to TAAD have been identified in genes that
regulate contractility, ECM genes, and specific contractile genes, which are all part of the
SMC-integrin-ECM continuum. Additionally, all existing mutations leading to TAAD can
be linked, directly or indirectly, to some component of this axis (12).
SMC phenotypic switching is also likely to play an important role in the disease
process. In an elastase perfusion model of abdominal aneurysms, phenotypic switching
occurred, characterized by decreased levels of SM α-actin and SM22α and increased
expression of MMP2 and MMP9, and preceded aneurysm formation (75). Other studies
have shown that expression of proteoglycans and matrix metalloproteases (MMPs) are
upregulated in the vessel wall, consistent with a more synthetic SMC phenotype. A mouse
model of MFS harboring a heterozygous mutation for Fbn1 displayed increased expression
of MMP2 and MMP9 along with decreased overall aortic contractility and increased
degradation of elastic fibers (24). Treatment of MFS mice with doxycycline, a nonspecific
MMP inhibitor, prevented medial degeneration, aneurysm formation, and aortic rupture
(76;77). One of the earliest histologic findings in medial degeneration is proteoglycan
accumulation within the aortic wall (22). Data from our lab indicate that this accumulation
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occurs at least in part through the induction of stretch-induced signaling pathways (Lafont et
al., manuscript submitted). Inflammation, angiotensin II signaling, and oxidative stress
represent other factors involved in the development of TAAD (21;78;79). Additionally,
SMC loss and/or SMC proliferation play a role in TAAD pathogenesis. Some debate exists,
however, over whether SMC loss, SMC proliferation, or a combination of both occurs in
aneurysms (80-82). Upon pathologic examination of aneurysmal aortic tissues, focal areas of
SMC loss within the tissue are a clear and common finding. However, some studies have
reported increased overall medial area combined with no change in SMC density in TAA,
suggesting an increase rather than a decrease in SMCs (82). It is possible that an early
proliferation is present, followed by later apoptosis and loss of SMCs. However, the specific
contribution of cell proliferation to TAA formation is currently not known.
A growing body of evidence strongly suggests that SMC contractile dysfunction is
one of the primary underlying defects leading to aneurysm formation, but the specific
mechanisms by which SMC-specific contractile gene mutations cause contractile
dysfunction and aneurysm formation are not yet known. Also, vascular disease in
individuals heterozygous for contractile mutations is not confined just to the aorta. ACTA2
and MYH11 mutations lead to development of early onset coronary artery disease and
stroke, in addition to TAAD. The segregation of additional vascular diseases in individuals
heterozygous for these mutations represents a novel disease phenotype (83). A conclusive
explanation of how aneurysms and occlusive diseases are caused by a single missense
mutation is lacking. Investigation into the mechanisms leading to disease in these
individuals should provide vital information about aneurysm formation, and may also
provide insight into pathogenesis of these additional major cardiovascular diseases. Our
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overall hypothesis for this study is that that SMC-specific contractile gene mutations lead to
both aneurysms and occlusive diseases through disruption of contractile filaments and loss
of SMC contractility, coupled with a gain of function effect of the mutation, leading to
increased SMC proliferation.
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CHAPTER II
CHARACTERIZATION OF THE VASCULAR AND CELLULAR PHENOTYPE IN
TAAD PATIENTS HETEROZYGOUS FOR MYH11 MUTATIONS

19

Background
A study reported inheritance of thoracic aortic aneurysms/dissections associated with
PDA in a single small family (84). Patent ductus arteriosus (PDA) results from a failure of
the ductus arteriosus, the fetal blood vessel connecting the pulmonary artery to the aortic
arch, to close properly at birth. Subsequently, Van Kien et al described familial TAAD
accompanied by PDA in a large French family (85). The disease in this family was not
associated with any other known locus for TAAD, or any other known locus for PDA. The
disorder was hypothesized to occur due to a single gene defect (85). This hypothesis was
confirmed when the disease in the French family was mapped to a single locus on
chromosome 16p12.2-p13.13 using a genome-wide scan followed by fine mapping of the
locus using microsatellite markers (86). In 2006, MYH11 was identified as the diseasecausing gene at this locus through sequencing in the critical interval on chromosome 16p
(33). A heterozygous missense mutation and a splice-site mutation leading to deletion of
exon 32 were identified in the French family, and a 72-base pair deletion in exon 28 was
identified in the American family, whose TAAD/PDA had been previously reported in 2001.
The mutations in both kindred were predicted to affect the coiled-coil structure of myosin,
disrupting assembly of myosin filaments within the cell (33). Subsequently, our lab
identified unique MYH11 missense mutations in two unrelated families with the combined
phenotype of TAAD and PDA (36). In the first family, an R712Q mutation was found in the
ATPase head domain of myosin and was predicted to disrupt the ATPase activity. Two
closely linked missense mutations, at R1275L and L1264P, were identified in the second
family. Both residues are located on the coiled-coil domain of myosin, but only L1264P was
predicted to disrupt coiled-coil formation (36).
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MYH11 is the second gene to be associated directly with non-syndromic familial
TAAD. Although MYH11 mutations are relatively rare, they represent the first TAAD
mutations found in a SMC-specific contractile gene, and study of the cellular effects of these
mutations should yield important information about TAAD pathogenesis. All of the families
assessed both by Zhu et al. and Pannu et al. displayed an inheritance pattern similar to
TAAD caused by other mutations, including variable age of onset and decreased penetrance
(33;36). Individuals with MYH11 mutations were found to have increased aortic stiffness
due to decreased compliance and distensibility prior to demonstrating aortic enlargement
(86). Aortas of patients heterozygous for MYH11 mutations showed typical features of
medial degeneration, including fragmentation and loss of elastic fibers, areas of SMC loss,
and accumulation of proteoglycans (33). Both the wildtype and mutant protein were
expressed in equal amounts in the aortic wall; however, MYH11 in the mutant aortic tissue
was found to be less stable. Normal immunostaining of MYH11 was observed in frozen
aortic tissue from patients compared with controls, but MYH11 staining was absent in
formalin-fixed tissues from patients, suggesting that the MYH11 mutations render the
protein more susceptible to denaturing by formalin fixation. Additionally, labeled mutant
and wildtype constructs containing the rod domain failed to co-localized when both were
expressed in Rb-1 cells (rabbit SMCs). Based on these data, the authors suggested that the
mutant protein behaved in a dominant-negative manner (33).
Eight myosin heavy chain isoforms are expressed in muscle tissue, and multiple
other isoforms exist as well (87). SM-MHC is an essential component of the SMC
contractile apparatus, as shown by studies of knockout mice. SM-MHC knockout mice do
not survive more than 72 hours after birth. These mice appear to be starved, and display a
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failure of proper bladder emptying, along with delayed closure of the ductus arteriosus,
demonstrating the importance of this protein for proper SMC contractile function (88).
Mutations in other myosin heavy chain isoforms also emphasize the indispensability of this
protein in muscle contraction, and provide supporting evidence that MYH11 mutations have
deleterious effects on SMCs. Mutations in MYH7 cause hypertrophic cardiomyopathy (89).
Structural analysis of the MYH11 mutations showed that the R712Q mutation present in one
family is heterologous to the R705 mutations in MYH9 that lead to hereditary deafness (36).
The mutation in this nonmuscle myosin (myosin IIA) results in decreased stability of the
protein structure, and reduced ability of the mutant myosin to couple ATPase activity with
cell movement, resulting in decreased cell motility (90;91). Therefore, the mutation at R712
in MYH11 is likely to also disrupt function of myosin within the cell.
Little is currently known about the specific pathogenic mechanisms associated with
MYH11 mutations. Some initial insight can be gained, however, through studies on
mutations in other myosin heavy chain isoforms. Mutations in cardiac-specific α-actin and
β-myosin cause familial hypertrophic cardiomyopathy (92). The disease is characterized by

myocyte disarray and hypertrophy, and accumulation of extracellular matrix (92).
Additionally, increased levels of mitotic and trophic factors, including insulin-like growth
factor 1 (IGF-1), transforming growth factor β1 (TGF-β1), and platelet-derived growth
factor β (PDGF-B) have been found in the myocardium of a subset of HCM patients (9395). It has been hypothesized that altered cardiac contractility leads to increased production
of growth factors, which may in turn play a role in HCM pathogenesis (96;97). Long-term
overexpression of IGF-1 in mouse hearts leads to a phenotype of cardiac hypertrophy,
extracellular matrix accumulation, and myocyte disarray compared with wild-type hearts,
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consistent with this hypothesis (98). Angiotensin II (Ang II) signaling may also contribute to
HCM pathogenesis. AngII contributes to cardiac hypertrophy, and involvement of a reninangiotensin system in pathogenesis of HCM has been reported (99;100). Specifically, ACE
polymorphisms leading to increased ACE expression and concomitant increases in
hypertrophy in individuals with HCM have also been reported (101). However, others have
failed to find any association (102).
The same growth factors that are increased in HCM patients (TGF-β, PDGF, and
IGF-1) also induce proliferation in SMCs (103). This suggests that the contractile defect
may lead to the production and release of growth factors which, along with other stimuli,
may be driving increased cellular proliferation in focal areas of the diseased tissue.
Therefore, we hypothesized that MYH11 patients’ pathology is similar to the pathology
observed in HCM.

Materials and Methods
SMC isolation and culture
All studies involving human subjects were approved by the institutional review
board at the University of Texas Health Science Center at Houston (UTHSCH), and
informed consent was obtained from all study participants. SMCs, frozen aortic tissue, and
paraffin-embedded tissue were obtained from one patient heterozygous for two closely
linked MYH11 mutations (L1264P and R1275L) and from controls who died of causes
unrelated to vascular disease, and were processed according to an established protocol (21).
An available H&E slide from a second patient heterozygous for a MYH11 R712Q mutation
was also obtained. Adventitial and intimal layers were removed from the aortic tissue. The
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remaining medial tissue was minced and digested in Waymouth’s media (supplemented with
2.5 mM L-glutamine, 1 mM MEM non-essential amino acids, 100 mM Hepes buffer,
sodium bicarbonate, and 1x antibiotic/antimycotic) and an enzyme mixture containing
elastase type I (0.01875mg/mL), collagenase type I (0.1mg/mL), and soybean trypsin
inhibitor (0.025 mg/mL). After 16 hours of incubation, enzymes were inactivated using FBS
followed by SmBm containing insulin, rhEGF, rhFGF, antibiotic/antimycotic, and 15% FBS
(Lonza). After centrifugation to remove remaining adventitial fat and any remaining
Waymouth’s media, tissue pieces were seeded into T25 flasks, and allowed to adhere for 4-6
weeks until SMCs migrated out of the tissue. SMCs were cultured in complete SmBm and
passaged upon confluence.

RNA isolation
Cells were seeded at confluence into 60 mm dishes and allowed to adhere overnight.
Cells were harvested following 18 hours of serum starvation (in media containing antibiotics
only and not supplemented with serum or growth factors), and RNA was isolated using
phenol-chloroform extraction (Trizol or Tri Reagent), according to the manufacturer’s
instructions. RNA samples were randomly tested for quality and purity using an Agilent
Bioanalyzer. If necessary, RNA was purified using the RNeasy mini kit according to the
manufacturer’s instructions (Qiagen).
RNA was isolated from whole tissue using a similar phenol-chloroform extraction
protocol. Briefly, small pieces of frozen tissue were minced in Trizol solution (Invitrogen)
and then homogenized using a Polytron tissue homogenizer. Samples were centrifuged at
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high speed for 30 minutes at 4ºC to remove tissue pieces. Supernatants were transferred to
new tubes, and RNA isolation was continued according to the manufacturer’s instructions.

Gene expression analysis
50ng of total RNA from each sample was reverse transcribed in triplicate using a kit
from Applied Biosystems. Quantitative PCR was carried out using pre-designed Taqman
gene expression assays (Applied Biosystems, Foster City, CA) on either an ABI 7000 or
ABI 7700 according to the manufacturer’s instructions, with the exception that the final
reaction volume was 20µL instead of 50µL. Thermal cycling parameters were as follows:
95.0ºC for 10 minutes, followed by 40 cycles of 95.0ºC for 15 seconds and 60.0ºC for 1
minute. Relative gene expression levels were calculated using the ∆∆CT method, using
GAPDH as an endogenous control. Student’s T-tests were used to determine statistical
significance.

Histology
H&E and Movat’s pentachrome stains were provided by the University of TexasMedical School pathology core and Texas Heart Institute pathology core, respectively.
Toluidine blue staining of cells was also performed by the UT pathology core.
Immunostaining of paraffin-embedded sections was performed as follows. Tissues
were deparaffinized and rehydrated using a series of xylene, ethanol, and PBS washes for
2x5 minutes for each wash: xylene, 100% EtOH, 95% EtOH, 70% EtOH, and 1x PBS.
Antigen retrieval was accomplished using 10mM citrate buffer, pH=6.0. Sections were
submerged in citrate buffer and microwaved at 50% power for 9 minutes, followed by 1
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minute at full power. Sections were monitored carefully to ensure that they did not dry out.
Following antigen retrieval, sections were allowed to cool in citrate buffer for 40-60
minutes. Sections were blocked for 1 hour at room temperature in normal serum from the
same species used to generate the secondary antibody (Vector Labs), and were incubated
with primary antibody overnight at 4ºC (Table 1).
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Table 1. Antibodies and dilutions.
Primary antibodies
antibody
β-actin
CD3
CD68
CTGF
p-ERK1/2
ERK1/2
pY397 FAK
FAK
Gapdh
Gapdh
IGF-1
SM α-actin
PAI-1
PCNA
phalloidin-Texas Red
pSmad2/3
tensin
vinculin
von Willebrand factor
zyxin
antibody or fluorophore
rabbit-HRP
mouse-HRP
goat-AP
mouse-AP
rabbit-AP
mouse-FITC
Fluorescein-streptavidin
Texas Red-streptavidin

company
species
IB
Sigma
mouse
Santa
Cruz
rabbit
Santa
Cruz
rabbit
Santa
Cruz
rabbit
Cell
Signal
rabbit
1:1000
Cell
Signal
rabbit
1:1000
Millipore
mouse
1:750
Santa
Cruz
rabbit
1:500
Abcam
rabbit
1:2000
Fitzgerald
mouse
1:20,000
Santa
Cruz
rabbit
Sigma
mouse
1:5000
Santa
Cruz
rabbit
Zymed
mouse
Invitrogen
n/a
Santa
Cruz
rabbit
Santa
Cruz
rabbit
Sigma
mouse-FITC
Dako
rabbit
Santa
Cruz
goat
Secondary antibodies and fluorophores
company
Jackson Immunoresearch
Jackson Immunoresearch
Santa Cruz
Vector Labs
Vector Labs
Jackson Immunoresearch
Vector Labs
Vector Labs

application
IB
IB
IF
IHC
IF, IHC
IF
IF
IF

IHC

IF
1:100

1:50
1:50
1:50

1:50

1:25
1:200

1:100

1:50
pre-diluted
1:40
1:50
1:25
1:500
1:200
1:25
dilution
1:2000-1:5000
1:2000-1:20,000
1:100
1:200
1:100-1:200
1:100-1:200
1:100
1:100

************************************************************************
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The following day, tissue sections were washed 2x in PBS and incubated with the
appropriate secondary antibody (Vector Labs) for 1 hour at room temperature, at a 1:200
dilution. Sections were washed 2x in PBS, incubated for 1 hour with a working dilution of
avidin-biotin conjugating reagent (Vector Labs), and washed 2x in PBS. A Vector Red
substrate kit was used to visualize immunostaining, and sections were counterstained with
hematoxylin, dehydrated, and mounted with coverslips using Permount (Fisher). Specimens
were viewed and photographed using an Olympus BX60 microscope (Olympus). Images
were processed and prepared for publication using Adobe Photoshop 6.0.
For toluidine blue staining, SMCs were seeded at a density of 5000 cells per 22 mm
glass coverslip, allowed to attach overnight, serum starved for 24 hours, and fixed with 4%
paraformaldehyde for 10 minutes. Toluidine blue staining was performed by the
Histology/IHC Laboratory at The University of Texas Medical School.

TGF-β1 treatment of SMCs and immunofluorescence
SMCs were seeded onto 22 mm glass coverslips at a density of 5,000 cells per
coverslip and allowed to attach overnight before serum starving. Following 24 hours of
serum deprivation, media was replaced with fresh serum-free media containing TGF-β1
(5ng/mL). Cells were fixed in 4% paraformaldehyde 72 hours post-TGF-β1 treatment.
Coverslips were blocked for 30 minutes in PBS containing 1% BSA and 0.1% Tween20,
and incubated overnight with primary antibody at 4ºC. The following day, coverslips were
incubated with a FITC-conjugated mouse secondary antibody (1:200, Jackson
Immunoresearch, West Grove, PA) for one hour followed by Texas Red-conjugated
phalloidin for 30 minutes, and were mounted onto slides with Vectashield mounting medium
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with DAPI (Vector Labs, Inc., Burlingame, CA). Table 1 lists antibody and fluorophore
concentrations used. Immunofluorescently labeled SMCs were viewed and photographed
using an Axioskop40 microscope, Axiocam MRm camera, and Axiovision software (Zeiss,
Thornwood, NY).

Cell counting
Ten high-powered fields (400x) were photographed of each SM α-actin stained
aortic tissue sample from two controls, and from the sinuses of Valsalva and ascending aorta
of the MYH11 patient. SM α-actin positive cells from the high-powered fields were counted
and averaged. To assess the number of actively proliferating cells, similar photographs were
taken of ten high-powered fields from each PCNA stained aortic tissue from patient and
controls. Both the total number of cells and the number of PCNA positive cells from each
section were counted, and the percent of actively proliferating cells was calculated. Data are
represented ± S.D., and statistical significance was determined using a Student’s T-test.

Organ culture and ELISA
A previously established protocol was used in order to assess the secretion of
cytokines from whole aortic tissue of patients and controls (104;105). Stock solution of ITS
was prepared, containing 0.5mg/mL insulin, 0.5 mg/mL transferrin, and 0.5 µg/mL sodium
selenite (Sigma-Aldrich, Inc.). 10µl of ITS stock solution was added to 990ul DMEM
containing 0.1% BSA. Whole aortic tissue segments from the MYH11 patient and two
unaffected controls were isolated, excess fat tissue was removed, and tissue was weighed to
ensure that equal amounts of tissues were used for the organ culture. Aortas were completely
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submerged and incubated in the DMEM-ITS solution for 3 hours at 37ºC. The tissue culture
supernatant fraction was collected and immediately frozen in 200µL aliquots and stored at 80ºC until analysis. Secretion of a panel of cytokines was analyzed using a Bio-Plex
Suspension Array System (Bio-Rad Laboratories, Inc.), and was performed as previously
described (104). An ELISA was performed to quantify Ang II production. Organ culturing
was performed by Dr. Yaozhong Liu, and the Bio-Plex cytokine assay and Ang II ELISA
were performed in collaboration with the Brasier lab at University of Texas Medical Branch
in Galveston.

Results
Unique vascular pathology in two patients heterozygous for MYH11 mutations
Staining of aortic tissue with Movat’s pentachrome stain provided the advantage of
being able to visualize multiple components of the vascular wall simultaneously. This stain
labels cells red, proteoglycans blue, collagens yellow, elastic fibers black, and nuclei violet,
allowing for rapid identification of various features of medial degeneration. Aortic tissue
from one patient heterozygous for two closely linked MYH11 missense mutations (L1264P
and R1275L) showed typical features of medial degeneration, including fragmentation of
elastic fibers, accumulation of proteoglycans, and some areas of SMC loss, consistent with
findings by Zhu et al (33). SM α-actin immunoreactivity also appeared to be normal in these
tissues (data not shown). H&E staining of aortic tissue was available from one additional
patient heterozygous for a different MYH11 mutation (R712Q). In contrast to both the
control aorta and the aorta of a patient with Marfan syndrome, both aortas from patients with

30

MYH11 mutations displayed areas of SMC accumulation within the medial layer (Figure II1).

Figure II-1. Aortic pathology associated with MYH11 mutations. H&E staining showed
normal alignment of SMCs in control (A) and a Marfan patient (B), but focal areas of SMC
hyperplasia and disarray in two MYH11 patients (C, R712Q mutant and D, L1264P mutant).
SMC hyperplasia was particularly apparent in the vasa vasorum of the MYH11 patient. H&E
staining of control (E) and MYH11 L1264P mutant (F) aortic tissue showed enlargement of
the vasa vasorum coupled with luminal narrowing in some vessels, whereas other vessels
appeared normal, as indicated by arrows. SM α-actin staining revealed normal vasa vasorum
in the control (G), and confirmed that vessel thickening in the MYH11 patient was due to
SMC hyperplasia (H). Movat staining of the aortic media from control (I) and patient (J)
showed typical features of medial degeneration in the MYH11 patient, including
proteoglycan accumulation (blue), fragmentation and loss of elastic fibers (black), and focal
areas of SMC loss. Von Willebrand factor staining showed that the MYH11 patient had a
dramatic increase in the number of small vessels penetrating deep into the medial layer (L)
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compared with controls (K). Scale bars represent 100 µm. Reprinted by permission from
Oxford University Press (36), copyright (2007).
**************************************************************************
Additionally, SMCs in areas of the media were oriented in random directions, in contrast to
controls, which had SMCs and elastic fibers organized in concentric layers perpendicular to
the axis of mechanical stretch. Although hyperplasia has been reported in TAA
development, aneurysms are often characterized by SMC loss (19;80;82). The combination
of hyperplasia and cellular disarray represent a novel aortic phenotype in TAAD patients.
In addition to cellular disarray and accumulation in the media, a number of vessels in
the vasa vasorum of the MYH11 patient heterozygous for an L1264P mutation showed
enlargement and thickening, based on H&E staining. Staining for SM α-actin and
counterstaining for nuclei confirmed that this thickening is due to SMC proliferation
(Figure II-1). Thickening occurred in some, but not all, of the vasa vasorum, suggesting that
the contractile mutation is the primary defect, and a secondary insult to the vessel wall
triggers the hyperplastic response.
At the time of surgical aortic repair, the surgeons noted an unusual, visible increase
in vascularity in this particular patient. Von Willebrand staining, specific for endothelial
cells, was used to confirm the increased vascularity. In normal aortic walls, the vasa
vasorum are mainly confined to the adventitia and the adventitia-media border. In sharp
contrast to controls, the MYH11 patient showed a dramatic increase in the number of small
blood vessels penetrating into the medial SMC layer of the aortic wall (Figure II-1).

Increased proliferation and accumulation of SMCs in the MYH11 aorta
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Counting of SM α-actin positive cells in aortic tissue sections from the ascending
aorta of two controls, and sections taken from the sinuses of Valsalva and from the
ascending aorta in the MYH11 patient revealed a significant increase in cell number in the
patient’s aorta (Figure II-2).

**
**

**

**

Figure II-2. SMC hyperplasia and increased SMC proliferation due to MYH11 mutations.
(A) Significantly greater numbers of SM α-actin positive cells were found in MYH11 aortic
tissue, and this was consistent for tissue taken either from the aneurysmal portion of the
aorta or from the sinuses of Valsalva. (B) Immunostaining of tissues with PCNA, a
proliferative marker, showed a significantly higher percentage of actively proliferating
SMCs in the medial layer of the patient’s aneurysmal tissue compared with controls and
with the sinuses of Valsalva. Error bars represent S.D. **p<0.01. Reprinted by permission
from Oxford University Press (36), copyright (2007).
**************************************************************************
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This observation was significant both in the undilated aortic root (sinuses of Valsalva) and
in the aneurysmal portion of the aorta (ascending). These data confirm that the increase in
cellularity is due to increased numbers of SMCs rather than inflammatory cells or a different
cell type. To determine whether these cells represented actively proliferating SMCs, we
immunostained the cells for PCNA, a nuclear marker for actively proliferating cells, and
counted the number of PCNA positive nuclei as well as the total number of nuclei under
high power magnification. A significantly higher percentage of SMCs in the patient’s
ascending aorta, at the site of aneurysm formation, were actively proliferating, compared
with the controls (p<0.01). However, although increased nuclei were present in the patient’s
sinuses of Valsalva, no significant difference in the percent of PCNA positive cells was
found between the sinuses and the controls. There was a significantly higher percentage,
however, in the number of actively proliferating cells in the patient’s ascending aneurysm
compared with the patient’s sinuses of Valsalva (p<0.01). Although myocyte hypertrophy is
one of the hallmark features of HCM, toluidine blue staining did not reveal any apparent
differences in cell size in the MYH11 patient compared with controls (data not shown).

Increased IGF-1 but not TGF-β1 or PDGF-B expression
Since TGF-β1, PDGF-B, and IGF-1 were all reported to be increased in tissues of
HCM patients, we analyzed expression of these growth factors in our explanted SMCs, as
well as in whole frozen aortic tissue samples (93-95). IGF-1 transcript levels were
significantly increased in the patient’s SMCs, and IGF-1 immunoreactivity was increased in
the patient’s aortic tissue compared with controls. TGF-β1 was not increased, and PDGF-B
was decreased compared with the controls (Figure II-3).
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*

*

Figure II-3. IGF-1 and ACE expression are increased in MYH11 mutant SMCs and tissues.
(A) IGF-1 gene expression is significantly increased in SMCs explanted from the MYH11
mutant aorta compared with controls. In contrast, TGF-β1 and PDGF-B levels are not
significantly altered. (B) ACE gene expression is significantly increased in MYH11 SMCs
compared with controls. In contrast, other RAS components including renin (REN),
angiotensinogen (AGT), and angiotensin II type I receptor (AT1R) are not significantly
altered. Gene expression data are normalized to GAPDH, and error bars represent S.D.
*p<0.05. (C-F) IGF-1 immunoreactivity was increased in both the aortic media and
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hyperplastic vessels in the adventitia in the MYH11 tissue (D,F) compared with control
(C,E). Reprinted by permission from Oxford University Press (36), copyright (2007).
*************************************************************************
Increased TGF-β1 activation has been reported in aneurysms in a mouse model of Marfan
syndrome; therefore, we sought to determine whether pathways downstream of TGF-β1
were activated in the MYH11 cells and tissue (10). Phosphorylated Smad2/3 is an early
marker of activated TGF-β1 signaling; however, we did not find any difference in Smad2/3
phosphorylation in the patient aorta compared with controls (data not shown).
Immunostaining for two other downstream markers of TGF-β1 signaling, CTGF and PAI-1,
also failed to reveal any difference in TGF-β1 activation (data not shown). These data
suggest that TGF-β1 signaling is not increased in the MYH11 aorta. However, IGF-1
immunoreactivity was increased in the patient’s aortic tissue compared with controls
(Figure II-3). Thus, IGF-1 but not TGF-β1 or PDGF-B, is increased in response to MYH11
mutations.

Potential role for a local renin-angiotensin system in the disease process
Although the majority of IGF-1 in the body is produced in the liver and circulates
throughout the body, IGF-1 can also be locally produced in an autocrine/paracrine manner.
IGF-1 expression can be upregulated through multiple pathways in SMCs, including through
mechanical stress, oxidative stress, growth factor signaling, and Ang II-mediated signaling
(106). We also analyzed production of pro-angiogenic and pro-proliferative cytokines using
a multiplex ELISA, and found striking increases in MIP-1-α and MIP-1-β. MIP-1-α is of
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particular interest because Ang II infusion results in increased MIP-1-α production in the
aorta (104) (Figure II-4A).

Figure II-4. MIP-1α and MIP-1β expression are increased in MYH11 SMCs and tissues.
(A) Organ culture followed by a Bio-Plex cytokine assay revealed increased secretion of
MIP-1α and MIP-1β from the MYH11 aorta (n=1) into the culture media compared with
controls (n = 4). Concentrations are expressed in units of pg/mL. (B,C) MIP-1α and MIP-1β
gene expression were increased in MYH11 SMCs and aortic tissue, compared with controls.
Error bars represent SD. Bio-Plex cytokine assay was performed by Dr.Yao-Zhong Liu in
collaboration with The University of Texas Medical Branch at Galveston. Reprinted by
permission from Oxford University Press (36), copyright (2007).
**************************************************************************
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QPCR analysis of explanted SMCs and aortic tissues confirmed an increase in gene
expression of these cytokines, suggesting that these are being produced specifically by
SMCs rather than other cell types in the aortic wall (Figure II-4B,C). MIP-1α is expressed
in response to angiotensin II signaling, leading us to hypothesize that a local reninangiotensin system is contributing to the observed increase in IGF-1. Gene expression of
renin-angiotensin system components in aortic tissue and explanted SMCs showed an
increase in angiotensin-converting enzyme, but not renin, angiotensinogen, or angiotensin II
type I receptor. Data from explanted SMCs are shown in Figure II-3; data from whole
aortic tissue was consistent with the explanted SMCs. Due to the dramatic increase in ACE
expression, we expected to also find increased secretion of angiotensin II by the MYH11
SMCs. However, an angiotensin II ELISA, as well as angiotensin II immunostaining of
aortic tissue, failed to show a difference in angiotensin II secretion by the whole aortic tissue
section (data not shown).

Inflammation and MYH11 TAAD
Vascular wall inflammation is present in a subset of TAAD and may play an
important role in pathogenesis. Since MIP-1α and MIP-1β are inflammatory cytokines and
both the secreted cytokines as well as mRNA levels were increased in the MYH11 patient,
we hypothesized that inflammation is present in MYH11 TAAD pathogenesis. MIP-1α is
produced by macrophages; therefore, we hypothesized that medial tissue in the MYH11 aorta
would contain significant numbers of macrophages compared with control tissues. However,
immunostaining for CD3, a T-cell antigen, and CD68, a macrophage marker, did not reveal
any major inflammation. Counting of CD68 positive cells under high-powered fields failed
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to reveal a significant difference in the numbers of macrophages in the patient vs. the
controls (data not shown).

Disruption of contractile filament assembly or stability
The missense mutation L1260P is predicted to disrupt the structure of MYH11. This
mutation is located in the coiled-coil domain of the protein and is predicted to disrupt coiledcoil formation and/or stability (36). However, it was not known whether alterations in the
myosin filaments disrupted the structure of other contractile proteins within the cell. Initial
immunofluorescent staining did not show strong SM α-actin labeling; therefore, SMCs were
treated with TGF-β1, a known inducer of SMC differentiation, to induce increased
expression of contractile proteins. 72 hours post TGF-β1 treatment, MYH11 SMCs
expressed SM α-actin, but the actin was not organized into contractile filaments within the
cell, in contrast with controls (Figure II-5). These data support the idea that disrupting one
element of the contractile apparatus also disrupts other contractile elements within the cell
and ultimately leads to decreased contractile function.

Filamentous actin

α-SM actin

Merge, nuclei

control

MYH11
L1250P

39

Figure II-5. Decreased SM α-actin polymerization in MYH11 SMCs. Explanted control and
MYH11 mutant SMCs were treated with 5ng/mL TGF-β1 to enhance SM α-actin expression,
after initial immunostaining for SM α-actin failed to yield results. Phalloidin-labeled actin
filaments (red) remained unaltered in the mutant SMCs; however, SM α-actin filaments are
disrupted in the MYH11 mutant SMCs. Focal areas of SM α-actin staining were observed,
suggesting that filaments begin to form but are prohibited by defective MYH11 from fully
assembling by within the cell.
**************************************************************************

Discussion
We have described a novel pathology associated with MYH11 mutations, including
SMC hyperplasia and disarray in the aortic wall, hyperplastic vasa vasorum, and increased
IGF-1 expression, in addition to typical features of medial degeneration. The observed
disarray, growth factor production, and ECM accumulation were similar to findings in HCM
patients, with the exception that proteoglycan rather than collagen was increased in the
MYH11 patient. In contrast to HCM, we observed SMC hyperplasia rather than hypertrophy.
This hyperplasia is significant because some controversy exists over whether SMC loss or
SMC hyperplasia occurs in aortic aneurysms (80-82). In one study, SMC loss was reported
in approximately 50% of TAAs (19). Another study showed that SMC loss was important,
but the study focused on abdominal aneurysms, which differ from TAA in their etiology and
pathogenesis (80). More recently, a different study suggested that SMC hyperplasia is an
initial adaptive response during early stages of aneurysm formation (82). This idea is
supported by the fact that SMC hyperplasia was observed in the vasa vasorum of the MYH11
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patient, who had a rapidly expanding aneurysm at the time of surgical repair. Therefore,
identifying the pathways leading to SMC hyperplasia is important for understanding familial
TAAD.
Others have reported abnormal thickening of the vasa vasorum in thoracic aortic
aneurysms, and blockage of the vasa vasorum renders the aorta more prone to dissection
(19). The extent of vasa vasorum thickening appeared to be greater in the MYH11 patient
than in patients with FBN1 or TGFBR2 mutations, however. Future studies will determine
whether an increased amount of vasa vasorum thickening is commonly present in
individuals with mutations in other SMC-specific contractile genes.
In addition to SMC hyperplasia, the marked increase that we observed in IGF-1
warrants follow-up for several reasons. First, IGF-1 can be locally produced by SMCs, and
multiple studies have demonstrated that this leads to an increase in cell proliferation. For
example, treatment of rat vascular SMCs with exogenous IGF-1 induced an increase in
proliferation, and this effect was inhibited with an IGF-1 neutralizing antibody.
Additionally, exposing the rat SMCs to cyclic stretch caused both an increase in IGF-1
secretion and in cellular proliferation, which was also blocked by treatment with an IGF-1
antibody (107). Second, in addition to its role in SMC proliferation, IGF-1 plays an
important role in regulating contractility. Aortas from mice that chronically overexpress
IGF-1 generate more force when contracting than wildtype mouse aortas. Overexpression of
an inhibitor of IGF-1 action, IGF binding protein 4 (IGFBP4), prevents this increase (108).
Additionally, IGF-1 causes an increase in both α-actin and myosin expression in vascular
SMCs (108;109) The dual role for IGF-1 in SMCs, together with data from the MYH11
patient, suggest that IGF-1 may be increased in response to improper contractile filament
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assembly or stability, and may play a role in driving the observed SMC proliferation.
Further, the fact that IGF-1 can be pathologically increased in response to vascular injury
further emphasizes its potential importance in pathogenesis of TAAD in MYH11 patients.
For example, IGF-1 levels were increased in rat aortas that were surgically banded near the
renal artery to induce hypertension (110). Also, IGF-1 levels are increased in response to
arterial balloon injury (111;112). Additional studies have shown that increased IGF-1 levels
are capable of causing increased proliferation in response to vessel injury. In mice that are
genetically modified to overexpress IGF-1 in SMCs, disruption of the endothelium in the
carotid artery leads to increased SMC proliferation and migration (113).
Unexpectedly, experimental evidence suggested a potential role for a local reninangiotensin system in MYH11 disease pathogenesis. The increase in ACE expression by
explanted SMCs, along with increased secretion of MIP-1α, suggest that Ang II production
and signaling are increased in the MYH11 patient. Ang II is known to induce cardiac
hypertrophy, as well as SMC proliferation. Additionally, Ang II infusion is an established
model of abdominal aneurysms (114). However, contribution of a local renin-angiotensin
system is difficult to assess, and conflicting data exist as to whether alterations in reninangiotensin system components are associated with HCM. ACE is a circulating enzyme and
is secreted by endothelial cells. Therefore, it is possible that ACE expression is due to the
increased vascularity observed in the MYH11 patient. However, the fact that explanted
SMCs specifically express increased ACE does not support this possibility. Primary
endothelial cells are technically difficult to isolate and culture, and as much endothelium and
adventitia as possible are scraped away during SMC isolation; thus, the SMC explant
protocol used is unlikely to result in contamination of SMC culture with endothelial cells. It
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is also possible that the increased ACE expression in the MYH11 patient is due to a
polymorphism coincidental with the MYH11 mutation, similar to some cases of HCM (101).
The ACE gene was not tested for polymorphisms in this individual.
In contrast to findings in mouse models of Marfan syndrome, we did not find
evidence of increased TGF-β1 signaling in the MYH11 patient. TGF-β1 mRNA expression
was not significantly altered. Phosphorylated Smad2/3, an early marker for activated TGFβ1 signaling, was not increased in the patient’s aortic tissue. Additionally, the expression of

CTGF and PAI-1, two proteins known to be increased in response to TGF-β1 signaling,
remained unaltered. These data suggest that additional mechanisms other than dysregulated
TGF-β1 signaling are driving the disease process due to MYH11 mutations. The observed
increase in IGF-1, together with the established roles for IGF-1 in promoting SMC
contractility and proliferation, suggest a potential role for IGF-1 in MYH11 disease
pathogenesis.
Interestingly, in addition to TAAD and PDA, patients heterozygous for MYH11
mutations are also more likely to develop major occlusive cardiovascular diseases than
unaffected family members, in the absence of other cardiovascular risk factors. In our
families with identified MYH11 mutations and in the large French family originally used to
identify the mutations, 19% of individuals heterozygous for the mutation (5 out of 26)
developed either early onset stroke or early onset CAD, but these diseases were absent in the
family members who did not carry the mutation (Pannu et al, manuscript submitted).
Additionally, MYH11 mutations have been identified in patients with other forms of vascular
disease, including 3 different missense mutations in individuals with premature CAD, 5
alterations (3 novel and 2 present in CAD) in individuals with early onset stroke, and 7
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alterations in individuals with Moyamoya disease, which is a pediatric-onset ischemic stroke
syndrome due to intimal fibrocellular accumulation in arteries in the circle of Willis (Pannu
et al, manuscript submitted) (115).
One advantage of this study is that we were able to gain insight into aneurysmal
disease at its peak of progression, in contrast to many other tissue samples that are obtained
when the disease is more in its end stages. Although the mutation is rare and the sample size
for this study was very small, the fact that the tissue sample came from a very rapidly
expanding aorta provided us with a unique opportunity to gain insight into the disease
process, as well as generate new hypotheses for follow-up in other TAAD patients. While
we were conducting this study, mutations in multiple other SMC-specific contractile genes
were identified, and the data obtained from this study was able to provide a starting point for
analysis of subsequent contractile gene mutations.
One limitation of this study is that we did not directly assess disruption of myosin
contractile filaments in MYH11 mutant SMCs, either by immunofluorescence, due to
technical difficulties with antibody staining, or by assessing myosin motor activity through
ATPase assays. However, several lines of evidence, including more recent studies on several
MYH11 mutants, exist that argue in favor of the mutation disrupting contractile filaments.
First, both software-predicted evidence and in vitro data exist to suggest that contractile
function is disrupted. COILS software predicted a decrease in the probability of coiled-coil
formation in L1260P mutant MYH11 (36). The R712Q mutation is paralogous to a myosin
IIA mutation that has already been shown to uncouple ATPase activity from the myosin
motor as well as disrupt the thermal stability of the protein, contractile filaments are highly
likely to be disrupted by this mutation as well (36). Additionally, previous reports of MYH11
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mutations show a predicted disruption in coiled-coil formation as well as increased
denaturation of MYH11 filaments after formalin fixation, indicative of a less stable protein
(33). More recent in vitro assays have shown that a number of MYH11 mutations in the
ATPase head domain have reduced ATPase activity compared to wildtype (Pannu et al,
manuscript submitted). Second, immunofluorescence data suggest that SM α-actin filament
formation and/or stability is disrupted in the MYH11 mutant SMCs. The stoichiometry of
components of the contractile apparatus is highly regulated, and disruption of one
component easily leads to disruption of other components (116). This idea is supported by
the observation that Acta2-/- mouse aortas display fewer myosin thick filaments than
wildtype, as assessed by electron microscopy (117). Therefore, MYH11 contractile
filaments are likely to be disrupted by the mutations described in this study.
It is still unknown whether the MYH11 SMCs are inherently more proliferative due
to structural alterations in the cell, or whether the observed proliferation is caused by
increased cellular stress and release of growth factors secondary to loss of cellular
contractility and loss of elastic fibers in the aortic wall. However, current data as well as
previous studies suggest that cell proliferation may play a key role in disease formation in
these individuals, and that IGF-1 may be a key factor in this process. While we cannot
completely exclude the involvement of other growth factors in the progression of this
disease, we propose that a decrease in SMC contractility and subsequent increase in cellular
stress induces the SMCs to overproduce IGF-1. The primary defect in the contractile
apparatus in the cell may hinder the ability of IGF-1 to increase contractility, while still
allowing for IGF-1-induced proliferation. Future studies will provide insight into the
mechanism and role of increased IGF-1 expression by aortic SMCs in the pathology of
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familial TAAD due to MYH11 mutations, as well as other mutations that result in a similar
vascular pathology.
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CHAPTER III
CHARACTERIZATION OF THE VASCULAR AND CELLULAR PHENOTYPE IN
TAAD PATIENTS HETEROZYGOUS FOR ACTA2 MUTATIONS
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Background
Six different actin isoforms have been identified: SM α-actin (ACTA2), cardiac αactin (ACTC), skeletal α-actin (ACTA1), smooth muscle γ-actin (ACTG2), cytoplasmic γactin (ACTG1), and cytoplasmic β-actin (ACTB) (118;119). The various actin isoforms are
highly homologous, with greatest variability found near the N-terminus, but are not
functionally redundant. SM α-actin comprises approximately two thirds of total actin and
40% of total protein within SMCs, making it the single most abundant protein in this cell
type (120;121).
Several studies have shown that actin isoforms can partially but not fully compensate
for loss of one isoform. Expression of Actg2 rescues the lethality in Actc-/- mice, and
partially but does not fully restore cardiac structure and function. Expression of Actc but not
Actg1 rescues the early postnatal lethal phenotype in Acta1-/- mice, demonstrating that in
some cases one actin isoform can potentially be substituted for another (122;123). Some
cardiac α-actin is expressed in humans in the absence of skeletal α-actin; however, the
cardiac α-actin expression is unable to prevent disease in these individuals. The exact
mechanisms determining specificity of each actin isoform are not known. All of these
studies provide support for the idea that defects in the SM α-actin protein cannot be
compensated for simply by the presence of other actin isoforms within SMCs.
Acta2-/- mice demonstrate decreased vessel contractility, underscoring the
indispensability of SM α-actin for proper SMC contraction (117). Surprisingly, complete
deletion of SM α-actin does not disrupt development of the cardiovascular system.
Increased expression of Acta1 and Actg2 in vascular SMCs in these mice was identified,
presumably to compensate for the loss of ACTA2 (117;124).
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Other actin isoforms play an important role in SMC contraction as well. βcytoplasmic actin and γ-actin make up 21% and 13% of total actin in vascular SMCs,
respectively (120). Some debate exists over whether the various actin isoforms in SMCs can
polymerize into the same actin filaments, or whether actin isoforms are compartmentalized
within the cell (125;126).
The discovery of MYH11 mutations leading to TAAD, along with novel pathologic
findings associated with these mutations, led to the following questions: Are additional
SMC-specific contractile proteins altered in TAAD? If so, do mutations in these other
contractile proteins lead to a similar vascular pathology? Subsequent identification of
mutations in SM α-actin provided answers to some of these questions. ACTA2 missense
mutations in TAAD were identified through linkage analysis and positional cloning (34). A
large family was recruited for study but did not have mutations in FBN1, TGFBR2, or
MYH11, and was not linked to any other known TAAD loci. The putative gene was mapped
to chromosome 10q23-24 using an Affymetrix array followed by microsatellite markers for
fine mapping of the critical interval. Twelve candidate genes were sequenced in the
identified region, and a missense mutation in ACTA2, R149C, was identified. Sequencing of
other familial TAAD samples revealed missense mutations at a total of eight different
residues, in fourteen families, with recurrent mutations at R149C in five families, and
R258C/R258H in three families (34). Additional mutations were subsequently identified
both by our lab group and by others, including previously identified as well as novel
mutations (83;127;128). Recently, de novo mutation of R179C leading to an exceptionally
severe systemic clinical phenotype was identified in 5 unrelated children and young adults
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(Dianna Milewicz, personal communication). All of the currently identified ACTA2
mutations are predicted to produce a mutant protein from the altered allele.
ACTA2 mutations showed a dominant inheritance pattern with variable age of
disease onset and decreased penetrance (34). A subset of ACTA2 mutation carriers also have
PDA, livedo reticularis, or iris flocculi. Livedo reticularis is a condition caused by persistent
occlusion of dermal capillaries leading to a purplish, netlike rash mainly on the upper and
lower extremities, and iris flocculi are neoplastic cysts found in the iris. Since SMCs are
present in the iris, it is possible that mutations in ACTA2 may both disrupt contractile
function and enhance proliferation, leading to cyst formation (127). Surprisingly, the
penetrance for TAAD caused by ACTA2 mutations was relatively low (0.48), even though
the LOD score indicating that ACTA2 is indeed linked to TAAD was statistically significant,
with a value of 4.17 (34).
The mutations in SM α-actin are located throughout the gene, and are predicted to
have differing functional effects, with a common endpoint of disrupting actin
polymerization (34). N117, R118, and V154 may disrupt either nucleotide binding or
hydrolysis, and are located near the nucleotide binding cleft. Y135, R149, and T353 disrupt
the binding site for various regulatory and end-capping proteins. R292 may disrupt actin
polymerization due to its close proximity to residues involved in actin-actin interactions.
R258 mutations are predicted to disrupt actin interactions with nebulin (34).
The presence of livedo reticularis in some ACTA2 patients led to the hypothesis that
ACTA2 mutations cause vascular occlusive diseases in addition to TAAD. Upon
examination of family medical histories, early onset CAD, stroke, and Moyamoya disease
were found to segregate with ACTA2 mutations in affected families, and this was highly
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statistically significant. Further, the disease penetrance rose from 0.48 to 0.80 when
individuals with occlusive diseases were included in the analysis. When analyzed separately,
each major vascular phenotype showed a positive LOD score for linkage to the ACTA2 gene,
and the combined LOD score for all of the vascular phenotypes rose from 4.17 to 10.62 (83).
Therefore, it was concluded that ACTA2 mutations cause vascular occlusive diseases in
addition to TAAD. The fact that ACTA2 mutations are predicted to disrupt normal SMC
contractile function suggests that decreased aortic contractility contributes to aneurysm
formation. Interestingly, certain ACTA2 mutations are more highly associated with
premature CAD than stroke, while other ACTA2 mutations are more associated with
premature strokes and Moyamoya disease. Moyamoya disease is a bilateral occlusion of
arteries in the circle of Willis due to SMC hyperplasia in the intimal layer of the vessel, and
leads to early onset strokes (115). The most notable difference is between individuals with
R149C mutations, which caused mainly TAAD and CAD, and individuals with R258C/H
mutations, which caused mainly TAAD and stroke, along with Moyamoya disease (83).
Studies of mutations in other actin isoforms have provided valuable insight into
mechanisms that may be driving disease in individuals with ACTA2 mutations. ACTC
mutations cause idiopathic dilated cardiomyopathy and familial hypertrophic
cardiomyopathy (129;130). Mutations in either ACTB or ACTG1 lead to deafness, and ACTB
mutations also lead to developmental abnormalities and dystonia (131;132). ACTB
mutations were also reported to cause severe mental retardation and recurrent infections
(133). ACTA1 mutations cause skeletal myopathy, and more mutations have been found in
ACTA1 than any other actin isoform to date (134;135). Studies of ACTC and ACTA1
mutations provide the most valuable insight for our study, because several mutations in
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these genes are homologous to a number of mutations identified in ACTA2 patients. Five
mutations are found at homologous residues in both ACTA1 and in ACTA2 (34;83;135).
Each of these mutations are predicted to disrupt function of ACTA1 (135). Due to the highly
conserved nature of actins, these data, along with the fact that no polymorphisms have been
identified in the ACTA2 gene, indicate that the alterations in ACTA2 are pathologic (34).
Additionally, information gained from ACTA1 myopathies provide evidence that mutations
in actin isoforms act in a dominant negative manner to disrupt contractile function of the cell
(136).
Based these previous studies, the identified mutations in ACTA2 are predicted to
disrupt structure and function of the protein in a dominant negative manner. However, little
is known about the mechanisms underlying disease pathogenesis in these individuals.
Dysregulation of TGF-β1 plays an important role in the pathogenesis of aneurysms in MFS
(10). However mutations in MYH11, another contractile gene, did not lead to increased
TGF-β1 signaling but did lead to SMC hyperplasia, suggesting that mutations in SMCspecific contractile genes may result in a different mechanism of disease pathogenesis than
previously described mutations. Our data from MYH11 SMCs and tissues suggest a novel
proliferative pathology due to a contractile gene mutation, and subsequent studies identified
early-onset vascular occlusive diseases in patients with MYH11 mutations (Pannu et al.,
manuscript submitted). ACTA2 is the second SMC-specific contractile gene identified
leading to TAAD, and also causes early-onset occlusive diseases including CAD, stroke, and
Moyamoya disease. As mentioned previously, Moyamoya disease results from a progressive
stenosis of the internal carotid arteries due to intimal hyperplasia (115). Collectively, these
data suggest that ACTA2 mutations should also lead to a proliferative pathology.
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In summary, damaging mutations exist in most other actin isoforms, and studies
particularly in ACTA1 patients have shown evidence that the mutant protein disrupts
contractile filament structure and interferes with the functioning of the remaining wildtype
protein. Based on existing data in ACTA1 and ACTC mutant individuals and mice, and our
pathologic findings in the aortas of patients with MYH11 mutations, we hypothesize that
ACTA2 mutations disrupt SM α-actin filaments and lead to a proliferative vascular
pathology similar to MYH11.

Materials and Methods
SMC explant and culture
All studies involving human subjects were approved by the institutional review
board at the University of Texas Health Science Center at Houston (UTHSCH), and
informed consent was obtained from all study participants. SMC explant, culture, and
plating were performed as described in Chapter II.

Histology, Immunofluorescence, and Microscopy
Aortic tissues from 9 patients heterozygous for ACTA2 missense mutations and from
6 controls were obtained (Table 2).
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Table 2. Tissue samples used for study
aortic tissue samples
pedigree ID
mutation age
sex
TAA105 II:4
R258H
49
F
TAA166 II:2
Y135H
52
M
TAA174 III:3
R118Q
47
M
TAA313 II:2
T353N
49
M
TAA327 III:19
R149C
36
M
TAA327 IV:4
R149C
28
F
TAA327 IV:5
R149C
26
M
TAA455 II:11
R185Q
42
M
sporadic
I250L
43
M
coronary and cardiac samples
pedigree ID
mutation age
sex
TAA441:IV:3
R118Q
28
M
TAA441:III:6
R118Q
50
M
TAA015:III:1
R292G
53
F
controls
control ID
age
sex ethnicity
6437
48
F
NE
6701
68
F
NE
6625
47
M
H
2664
48
F
NE
7234
35
M
H
6559
69
M
H

ethnicity
NE
NE
NE
NE
NE
NE
NE
H
NE
ethnicity
NE
NE
NE

Table 2. Tissue samples used for study. Sample ID, ACTA2 mutation, age, gender, and
ethnic origin of patient and aortic and cardiac tissues, and control aortic tissues utilized for
study are listed. (For ethnic origins, NE = Northern European descent; H = Hispanic).
**************************************************************************
Coronary artery tissue from one patient and cardiac tissue from two patients became
available, and were also obtained and analyzed (Table 2). Histology and immunofluorescent
staining were carried out as described in Chapter II. For high-resolution images of SM αactin staining, deconvolution microscopy was performed using a DeltaVision Deconvolution
microscope system (Applied Precision, Inc.). Images were acquired and deconvolved using
SoftWoRx 3.5 software. Images were obtained using 40x and 60x oil immersion objectives.
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Cell proliferation assays
SMCs explanted from two patients heterozygous for ACTA2 missense mutations and
from two controls were plated in triplicate at a density of 10,000 cells per well in a 9-well
plate (Table 3).
Table 3. Cell strains used for cell proliferation studies
Smooth Muscle Cells
Family
TAA313
sporadic

Patient ID
II:2
MG5875

mutation
T353N
I250L

age
49
43

sex
M
M

Control ID
MG8131
MG8438

age
36
43

sex
M
F

sex
F
M
F
M
M
M
M
F
F

Control ID
MG3015
MG3032
MG3008
MG3018
MG3017
MG3019
MG3031
MG3033
MG3002
MG3027

age
23
26
32
36
38
41
43
48
49
53

sex
F
M
M
F
M
F
M
F
M
F

Fibroblasts
Family
TAA018
TAA174
TAA327
TAA041
TAA041
TAA455
TAA455
TAA105
TAA105

Patient ID
III:1
III:3
IV:4
II:3
II:6
II:12
II:8
II:3
II:4

mutation
P72Q
R118Q
R149C
R149C
R149C
R185Q
R185Q
R258H
R258H

age
27
47
30
37
32
42
50
36
49

Table 3. Cell strains used for cell proliferation studies. Age denotes the age of the individual
at the time that an aorta or skin biopsy was obtained. Reprinted from (83), with permission
from Elsevier.
**************************************************************************
After 24 hours, cells were placed in SmBm containing 0.2% FBS, and 5-bromo-2deoxyuridine (BrdU), which replaces thymidine during DNA synthesis, was added. 24 hours
post BrdU treatment, cells were fixed, and a BrdU ELISA was carried out according to the
manufacturer’s instructions (Millipore). Absorbance of each plate was read at 450nm, and
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this optical density reading was proportional to the amount of BrdU incorporation.
Experiments were repeated three independent times on SMCs between passage 2 and 5. A
Student’s T test was used to determine statistical significance, with p<0.05 considered
significant.

Quantitative Gene Expression
Total RNA was isolated and QPCR was performed as described in Chapter II. Data
are represented as mean ± S.D., and Student’s T tests were used to determine statistical
significance, with p<0.05 considered significant.

Results
Histologic features of ACTA2 TAAD
Initially we examined the histology of the ascending aorta in patients with ACTA2
mutations who underwent aortic surgical repair. We had access to nine aortas from patients
with the following mutations: R258H, Y135H, R118Q, T353N, R149C, R185Q, and I250L
(Table 2). Similar to the MYH11 aorta in Chapter II, we used Movat staining to visualize
multiple components of the vascular wall. Movat staining of aortic tissue revealed features
of typical medial degeneration as indicated by the accumulation of proteoglycans (blue) and
loss of elastic fibers (black) (Figure III-1A).
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A

B

Figure III-1. Aortic pathology associated with ACTA2 mutations. (A) Movat and SM α-actin
immunostaining of the media from control and ACTA2 mutant aortic tissues. Movat staining
revealed typical features of medial degeneration in ACTA2 mutant tissue compared with
control, including areas of SMC loss, proteoglycan accumulation (blue), lack of collagen
accumulation (yellow) and fragmentation and loss of elastic fibers (black). SM α-actin
immunostaining revealed areas of SMC hyperplasia and disarray compared with control. (B)
Both H&E staining and SM α-actin immunostaining showed hyperplastic vessels were
present in the adventitia in ACTA2 mutant aortic tissue but absent in control. The
hyperplastic vessels were both enlarged in size and showed luminal narrowing, and in some
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cases were completely occluded. SM α-actin immunostaining, along with von Willebrand
factor staining (not shown) confirmed that these were blood vessels and that the hyperplasia
was due to increased numbers of SMCs. Scale bars represent 100µm, and magnification for
each panel is indicated. Reprinted by permission from Macmillan Publishers Ltd: [Nature
Genetics] (34), copyright (2007). http://www.nature.com/
**************************************************************************
We also examined the aortas to determine whether features similar to the MYH11 aorta were
present, including disarray, focal areas with increased SMCs, and thickened vasa vasorum.
Similar to MYH11 mutations, aortas from ACTA2 patients showed increased SMCs in focal
areas, and we confirmed this by SM α-actin immunostaining (Figure III-1A). SMCs in the
patients’ aortas also displayed areas of random orientation with respect to each other, similar
to the disarray observed in the MYH11 aorta. The arteries in the vasa vasorum were also
enlarged and thickened in ACTA2 patients compared with similar arteries in control aortas.
Despite the enlargement, the vessels were stenotic, and in some cases were completely
occluded. We stained for an endothelial specific marker (von Willebrand factor, not shown)
and α-SM actin to confirm that these were blood vessels (Figure III-1B). Immunostaining
confirmed the identity of these structures as vessels, and also showed SMC hyperplasia.
Data from two R149C mutant aortas and one T353N mutant aorta are shown, and these are
representative of the enlarged vessels that were present in every ACTA2 mutant aorta where
adventitial tissue was visible (the adventitial layer was completely missing in one tissue
sample). We also used Movat-stained tissue samples to examine the integrity of the internal
elastic lamina, and determine whether the proliferation in the vessels was confined to the
media, to a neointimal layer, or a combination of both. Movat staining confirmed that the
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internal elastic lamina of these vessels remained intact, and that vessel thickening was due to
increased SMCs in the medial layer, rather than neointimal formation (not shown).

SMC proliferation and occlusion in other arteries
During the course of our study, coronary artery and/or cardiac tissue from three
individuals with ACTA2 mutations became available for pathologic examination (Table 2).
Coronary artery tissue was obtained from a 28 year old male of Northern European descent
heterozygous for an R118Q mutation who died from an acute aortic dissection. He did not
have any known risk factors for cardiovascular disease or any diagnosis of CAD prior to
death. Initial H&E staining showed 70% narrowing of the vessel due to an atherosclerotic
lesion combined with increased cellularity in both the medial and intimal layers of the
vessel. We used a Movat stain to determine which ECM components were increased in the
vessel wall, and immunostained with SM α-actin to confirm that the increased cellularity
was due to increased SMCs. We observed that the lesion in this individual was due to an
accumulation mainly of cells rather than lipids, in contrast to typical atherosclerotic plaques.
SM α-actin immunostaining confirmed that the accumulated cells were SMCs (Figure III2A).
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Figure III-2. ACTA2 mutations are associated with SMC hyperplasia and SMC proliferation
in culture. (A) Coronary artery tissue from a 28-year-old male heterozygous for an R118Q
ACTA2 mutation showed 70% narrowing of the vessel, and this was due to a fibrocellular
atherosclerotic plaque. Movat staining showed that this lesion was due mainly to
accumulation of cells, and SM α-actin staining confirmed that these were SMCs. Scale bars
represent 1.0mm in the top two panels (magnification 40x) and 200µm in the bottom two
panels (magnification 200x). (B) Epicardial arteries from two individuals heterozygous for
ACTA2 mutations showed abnormal thickening. H&E, Movat, and SM α-actin staining are
shown. The first individual (TAA441:III:6) had an R118Q mutation, and the second
individual (TAA015:III:1) had an R292G mutation. (C) Cell proliferation assays showed
that SMCs explanted from patients heterozygous for ACTA2 mutations (n = 2) proliferated
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significantly more rapidly than matched control SMCs (n = 2), as quantified by ELISAs for
BrdU incorporation. Error bars represent S.E.M. and p-value is indicated. Reprinted from
(83), with permission from Elsevier.
*************************************************************************
Cardiac tissue was obtained from two patients, neither of whom were at high risk for CAD.
The first sample was from a male of Northern European descent heterozygous for an R118Q
mutation, who first had an acute aortic dissection at age 50, diagnosed with CAD at age 54,
and died at age 59 after having a chronic aortic dissection surgically repaired. Pathologic
examination of the tissue showed abnormal thickening of epicardial arteries. We used SM αactin and MOVAT staining to confirm that this thickening was due to SMC accumulation in
the medial layer. The second sample was from a 53 year old Northern European female
heterozygous for an R292G mutation, who died of unknown causes. Similar to the first
tissue sample, abnormal thickening of epicardial arteries was found and noted at autopsy
(Figure III-2B). Together, these data support the idea that pathologic changes due to
ACTA2 mutations are not just confined to the aorta but are present in multiple vascular beds,
including coronary arteries.

SM α-actin expression, polymerization, and localization
Based on predicted structural alterations due to ACTA2 mutations, we hypothesized
that SM α-actin filament formation would be impaired. To test this hypothesis, we
immunolabeled SMCs explanted from ACTA2 patients and matched controls with both SM
α-actin and phalloidin, which binds to all polymerized actin within the cell. Filaments in
control SMCs extended across the cell body and colocalized with total actin filaments within

61

the cell. ACTA2 patients also showed filaments composed of other actin isoforms, but little
to no SM α-actin-containing filaments. These data indicate that ACTA2 mutations result in a
decrease in formation and/or stability of SM α-actin filaments (Figure III-3).
All filamentous actin

SM α-actin

Merged, DAPI

Figure III-3. SM α-actin filament disruption due to ACTA2 mutations. Analysis of actin
stress fibers in SMCs explanted from control (top row) and ACTA2 mutant aortas (bottom
two rows). The left panels show phalloidin staining of total filamentous actin (red), the
middle panels show SM α-actin (green), and the right panels show a merged image. SM αactin filaments were greatly reduced in ACTA2 mutant SMCs. Double labeling of the SMCs
for total actin filaments showed that filamentous actin and SM α-actin were colocalized in
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the control SMCs. Little to no colocalization was observed in the ACTA2 mutant SMCs.
Scale bars represent 40µm; magnification = 400x. Reprinted by permission from Macmillan
Publishers Ltd: [Nature Genetics] (34), copyright (2007). http://www.nature.com/
**************************************************************************
Interestingly, in the two samples available for study, actin filaments were disrupted to
differing degrees. In SMCs heterozygous for an R118Q mutation, actin accumulated in the
perinuclear region of the cell, and little to no filament assembly was observed. A T353N
mutation resulted in formation of rodlike structures at the cell periphery. However, SM αactin filament formation was still greatly impaired, and filaments did not extend across the
cell as in the controls (Figure III-3). Explanted SMCs from a third individual, heterozygous
for an I250L mutation in ACTA2, showed too little ACTA2 expression initially to adequately
analyze by immunofluorescence. We treated SMCs from this patient and from matched
controls with TGF-β1, since it is a well known and potent stimulator of SMC differentiation.
Expression of ACTA2 was increased upon TGF-β1 treatment; however, no SM α-actin
filament formation was observed in these cells, and actin was accumulated mainly in the
perinuclear region (Figure III-4). Findings in this patient were similar to the R118Q mutant
SMCs in Figure III-3.
Filamentous actin

α-SM actin

Merge, nuclei

control

ACTA2
I250L
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Figure III-4. SM α-actin expression in TGF-β1 treated ACTA2 SMCs. Since SMCs from a
patient heterozygous for an ACTA2 I250L mutation expressed very low levels of SM αactin, these SMCs and matched controls were treated with 5 ng/mL TGF-β1. The left panels
show phalloidin staining of total filamentous actin (red), the middle panels show SM α-actin
(green), and the right panels show a merged image. 72 hours post TGF-β1 treatment, SM αactin expression was increased but failed to form filaments (green). In contrast, the SM αactin in controls formed filaments that colocalized with total actin in the cells.
**************************************************************************
Increased proliferation of ACTA2 mutant SMCs
Since multiple vessels from ACTA2 patients showed focal areas of SMC hyperplasia,
we hypothesized that this was due to an increase in SMC proliferation within the vascular
wall. We used BrdU incorporation assays to quantify DNA synthesis and determine whether
explanted SMCs from these individuals proliferate more rapidly in vitro. We found that
proliferation, as assessed by BrdU incorporation, was significantly increased in SMCs
explanted from patients with heterozygous ACTA2 mutations (n=2) compared with age and
gender matched controls (n=2) (Figure III-2C). These data are consistent with the
histologic data, both from aortic tissues and from coronary and epicardial arteries from
affected individuals, and indicated that ACTA2 mutations are associated with a proliferative
vascular pathology, similar to MYH11 mutations. These data are also consistent with
histologic findings in the MYH11 patient.

Increased IGF-1 but not TGF-β1 or PDGF gene expression and immunostaining
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Due to the similar proliferative pathology in tissues and SMCs from both MYH11
and ACTA2 patients, we hypothesized that IGF-1 would also be increased in ACTA2 mutant
tissues and SMCs similar to MYH11 tissues and SMCs. IGF-1 transcript levels were
significantly increased in two out of three SMC samples. The increase in IGF-1 was slightly
variable, however, since a third SMC sample also displayed a slight increase in IGF-1 gene
expression but this increase was not statistically significant (Figure III-5A).
A

B

Figure III-5. IGF-1 expression is increased in ACTA2 SMCs and tissues.
(A) IGF-1 gene expression is increased in ACTA2 mutant SMCs compared with matched
controls, and increases in two out of three of these samples were statistically significant.
Data are normalized to GAPDH. Experiments were performed in triplicate (control n=2;
ACTA2 patient n=1 for each separate mutation). Labels indicate the specific ACTA2
missense mutations, and error bars represent ± S.D. *p<0.05. (B) IGF-1 protein expression
in aortic media (B, top two panels) and adventitia (B, bottom two panels) is increased in
patients heterozygous for ACTA2 mutations. Immunostaining of IGF-1 in aortic tissues
produced variable results overall, but was consistently increased in patients with R149C
mutations.
*************************************************************************
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We also performed immunostaining using an IGF-1 antibody to determine whether IGF-1
protein expression in the aortic tissue was increased. Similar to findings in our QPCR
analysis, we observed increased immunoreactivity to IGF-1 in some but not all ACTA2
aortas. Despite some variability among samples, however, IGF-1 immunostaining was
consistently more intense in the aortas of patients heterozygous for R149C mutations and
was present in both the aortic media and in the hyperplastic vasa vasorum in these tissues
(Figure III-5B).

Discussion
In Chapter II we described a novel proliferative pathology due to MYH11 mutations,
and we hypothesized that additional mutations in SMC-specific contractile genes would both
disrupt the contractile filament structure within the cell and lead to a vascular pathology
similar to what we observed in the MYH11 aortic tissue. Consistent with our hypothesis,
heterozygous missense mutations in ACTA2 led to disruption of SM α-actin filament
formation in explanted SMCs, compared with controls. These data were also consistent with
structural predictions based on the locations of the various mutations within ACTA2. In
addition to disruption of SM α-actin filaments, ACTA2 aortas displayed a vascular pathology
similar to the MYH11 patient, with focal areas of increased SMC hyperplasia and disarray,
in both the media and in the vasa vasorum. We also found increased proliferation of ACTA2
mutant SMCs in vitro in static culture, compared with controls. These data suggest that a
contractile defect in SMCs leads to increased proliferation even in the absence of
mechanical stress, and further confirms our hypothesis that contractile mutations in ACTA2
and MYH11 lead to a common proliferative pathology.
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The incidence of early-onset CAD and stroke in ACTA2 mutant individuals raised
the question of whether this proliferative pathology was present in other vascular beds,
contributing to occlusive disease. We had the opportunity to analyze two cardiac tissue
samples and one coronary artery tissue sample from patients heterozygous for ACTA2
mutations, and we observed similar patterns of SMC hyperplasia, abnormal vessel
thickening, and luminal narrowing in all of these samples. These data indicate that the
proliferative pathology is indeed present in other vascular beds in affected individuals, and
suggest that inappropriate proliferation of SMCs may be involved in the premature CAD and
stroke due to ACTA2 mutations. Thickening and luminal narrowing of small vessels within
the heart has previously been reported in cases of hypertension(137;138).
In addition proliferative pathology similar to MYH11, ACTA2 patients’ SMCs and
tissues displayed increased IGF-1 gene and protein expression. As previously discussed,
IGF-1 is a regulator of both SMC contractility and proliferation (107;108;108;109). IGF-1 is
also upregulated in response to vascular injury (110-113). All of these studies suggest that
the observed increase in IGF-1 may be contributing to the hyperplasia in ACTA2 mutant
aortas. IGF-1 expression in some of the aortic tissues was variable, however. This variability
may be due either to the specific mutation in ACTA2 or due to the unavoidable fact that
tissue samples were collected at various stages of disease progression. Individuals
heterozygous for R149C mutations consistently had higher levels of IGF-1 in aortic tissue
than individuals with other mutations. Unfortunately, explanted SMCs from R149C mutant
individuals were not available for study. Further experiments are necessary to determine
whether IGF-1 is driving SMC proliferation, particularly in the patients’ samples with the
highest levels of IGF-1 expression.
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One distinct advantage of this study is the availability of clinical data, which enabled
correlations of the in vitro cellular phenotype to be made with the clinical presentation of
disease. Pathologic analysis of blood vessels from ACTA2 mutant individuals suggested that
vessel occlusion also played an important role in the disease process, and this finding
correlated with the early onset CAD and stroke present in families carrying ACTA2
mutations. Conversely, particularly in the case of livedo reticularis (LR), the clinical
findings were able to inform the direction of research. In the family originally used to map
and identify the first ACTA2 mutations, LR was a near-100% predictor of which individuals
carried the mutant allele(34). The presence of LR, a known vascular occlusive condition,
also prompted further analysis of occlusive diseases in ACTA2 mutant individuals and
families.
Similar to the experiments using MYH11 SMCs and tissues, this study was limited
by sample size and the availability of aortic tissues and explanted SMCs. Development of
specific model systems for studying the cellular effects of ACTA2 mutations will allow for a
better assessment of the in vitro cell proliferation and the specific molecular mechanisms
driving the proliferation, and should be particularly useful in elucidating the role of IGF-1 in
this process.
Our data from this study support both a decrease in SMC contractile function and an
increase in proliferation due to ACTA2 mutations. SM α-actin filaments were disrupted in
mutant SMCs, providing evidence that the mutations lead to disruption in SMC structure.
Analyses of ACTA1 and ACTC mutations support the idea that missense mutations
disrupting formation of actin filaments also lead to decreased contractility (139;140). Study
of Acta2-/- mice shows that total loss of Acta2 decreases SMC contractility; the
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development of transgenic and knock-in mouse models will aid in determining whether
aortic contractility is altered due to mutation of Acta2 (117). Therefore, although the
evidence is indirect rather than a direct measurement of contractile function, our results
indicate a probable loss of SMC contractile function. Both the SMC hyperplasia in multiple
vascular beds and the increased SMC proliferation in vitro support a gain of proliferative
function due to ACTA2 mutations.
Individuals with early onset CAD or stroke in ACTA2 families lacked any of the
major risk factors for cardiovascular disease, including hypercholesterolemia, severe and
uncontrolled hypertension, or diabetes. These clinical data, along with the SMC
accumulation in vivo within blood vessels in multiple vascular beds, along with the
increased SMC proliferation in vitro, suggest that single missense mutations are capable of
triggering a proliferative response leading to vessel stenosis and occlusion. This represents a
novel pathway for development of occlusive vascular disease development due to a genetic
defect. Further, the increase in IGF-1 and the established roles of IGF-1 in SMCs suggest
that IGF-1 may be a key factor in driving proliferation and vessel occlusion. However, the
specific role of IGF-1, as well as the mechanism(s) driving increased IGF-1 expression in
the mutant tissues and SMCs, remain unknown.
In conclusion, ACTA2 mutations lead to disruptions in SM α-actin filament
assembly, increased SMC proliferation, and increased IGF-1 expression. Future studies will
focus on 1) developing a model system to overcome the difficulties with small sample size,
2) elucidating the specific roles that IGF-1 plays in driving proliferation in ACTA2 SMCs,
and 3) determining whether the increase in proliferation can be prevented, to delay the
progression of disease in affected individuals.
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CHAPTER IV
ESTABLISHMENT AND CHARACTERIZATION OF A MODEL SYSTEM FOR
DETERMINING MAJOR PATHWAYS DRIVING PROLIFERATION
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Background
Myofibroblasts are cells with biochemical and morphologic features of both
fibroblasts and SMCs and can arise from multiple cell types in numerous different organs
(141). The complex regulation of this transition is complex but has been studied extensively.
One of the hallmarks of myofibroblast differentiation is the expression of SM α-actin, but
myofibroblasts also express multiple other SMC-specific contractile genes (142). Many
different factors are capable of inducing myofibroblast differentiation in vitro and in vivo. In
vitro, mechanical force due to stretching, composition and rigidity of the substrate can
induce myofibroblast differentiation (143-145). Chemical modulators including TGF-β1 and
heparin can also induce differentiation (141;146). Antimitotic agents have also been found
to increase SM α-actin production (147). Cell density has also been shown to modulate the
effects of various treatments and external forces on myofibroblast differentiation, and cells
plated at low density gain a myofibroblast phenotype upon reaching confluence (148). In
vivo, latent TGF-β1 is released from its inactive form in the extracellular matrix after
mechanical stretch or injury, driving differentiation of myofibroblasts, which aid in wound
healing. It is not completely known whether the disappearance of myofibroblasts is due to
de-differentiation back into fibroblasts, apoptosis, or a combination of both (144;149).
Early events in myofibroblast differentiation involve TGF-β1/Smad signaling. TGFβ1 binds to type II TGF-β receptors, which form heterotetramers with type I receptors, and
are phosphorylated following TGF-β1 binding. Following receptor internalization, Smad
anchor for receptor activation (SARA) aids in recruiting Smad2 and Smad3 to the receptor
(150). Smad2 and Smad3 are phosphorylated, and the activated Smad2/3 complex
translocates to the nucleus and activates transcriptional targets, including SM α-actin,
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through a TGF-β control element (TCE) in the ACTA2 promoter (151). TGF-β1 also induces
the expression of integrins and ECM, including fibronectin and collagen, driving
autophosphorylation of FAK and subsequent activation of FAK signaling (152).
Later signaling events leading to SM α-actin protein accumulation within the cell are
dependent on cell adhesion, ECM production, and signaling through FAK. Expression of the
ED-A splice variant of fibronectin is required for TGF-β1-induced myofibroblast
differentiation (153). Since maintenance of the myofibroblast phenotype is dependent on a
stiff ECM, the sustained expression of SM α-actin may be dependent on cell adhesiondependent FAK signaling. In one study, a correlation was found between SM-α-actin levels
and both autophosphorylated and total FAK (152). In contrast, another group reported that
myofibroblast differentiation was enhanced in FAK-/- mouse embryonic fibroblasts (MEFs),
suggesting that at least in MEF cells, TGF-β1 is capable of activating additional pathways to
compensate for the loss of FAK in promoting SM α-actin expression (154). Together, these
studies show that myofibroblast differentiation is adhesion-dependent and is regulated by
FAK, but that other pathways are involved as well. Studies in 10 T1/2 cells have shown that
the PI3K/Akt pathway is involved in transformation of these cells to SMCs upon treatment
with TGF-β1 (155).
Differentiated myofibroblasts possess several distinct advantages as a model system
for studying the cellular effects of ACTA2 mutations: 1) samples could more readily be
obtained from affected individuals as well as normal controls, 2) samples heterozygous for a
wider range of ACTA2 mutations could be tested, and 3) dermal fibroblasts exhibit
phenotypic plasticity in certain culture conditions and can be induced to differentiate into
myofibroblasts that synthesize SMC-specific contractile proteins.
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Although preliminary data suggested that both ACTA2 and MYH11 mutations lead to
increased SMC proliferation, we chose to focus on ACTA2 mutations since they represent a
larger percentage of all familial TAAD. Insight gained from these studies should be
applicable to TAAD caused by mutations in other contractile proteins as well. The goals of
this study are to 1) establish myofibroblasts as a model system for studying ACTA2
mutations, 2) utilize this model system to confirm an increase in IGF-1 in a larger sample of
patients with ACTA2 mutations, and 3) determine the role of IGF-1 in cell proliferation due
to ACTA2 mutations. The importance of IGF-1 in SMC differentiation, as well as the ability
of IGF-1 to induce SMC proliferation, has been discussed previously (see Discussion,
Chapter II). Also, an extensive body of literature suggests that myofibroblasts expressing
SM α-actin are an adequate model system for our study. We hypothesize that ACTA2 mutant
myofibroblasts proliferate more rapidly than controls, similar to the cultured SMCs, and
that the proliferation occurs in an IGF-1 dependent manner.

Materials and Methods
Dermal fibroblast explant and culture
All studies involving human subjects were approved by the institutional review
board at the University of Texas Health Science Center at Houston (UTHSCH), and
informed consent was obtained from all study participants. Dermal fibroblasts were
explanted from 9 patients heterozygous for ACTA2 mutations and from 10 controls matched
for age and gender, using a previously established protocol. None of the controls had a
known history of vascular disease. All samples used for study are listed in Table 3 of
Chapter III. Small biopsies of dermal tissue were obtained from the forearm. Tissue was
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briefly washed in 70% ethanol, PBS, and DMEM, and epidermal and fatty layers of tissue
were removed. Tissues were minced and placed in 60mm dishes. A glass coverslip was
placed over the tissue pieces, and 3mL DMEM containing 10% FBS was added to the dish,
and media was changed twice a week. Cells were allowed to migrate out of the tissue, and
were trypsinized and seeded into flasks once multiple areas of confluence were apparent
under the coverslips. Fibroblasts were cultured in DMEM containing 10% FBS, and were
used for experiments at passage 2 through 5.

Myofibroblast protocol 1: Low density/high density plating
Low density and high density plating of dermal fibroblasts was done using a
published protocol, with minor modifications (148). Dermal fibroblasts were grown to
confluence in T75 flasks, and were plated at either 5 or 500 cells/mm2 in DMEM containing
10% FBS. Culture medium was replaced every three to four days. Upon reaching
confluency, cells were serum-starved for 24 hours and harvested for RNA and protein
analysis. Cells plated at high density reached confluence within 1 day or less, while cells
plated at low density did not reach confluence for nearly 2 weeks, and this time frame varied
somewhat among samples.

Myofibroblast protocol 2: TGF-β1 treatment
Dermal fibroblasts cultured in T75 flasks were allowed to remain at confluency for
4-5 days prior to each experiment. Cells were plated in duplicate at 80-100% confluency in a
final volume of 2mL into 60-mm dishes, to allow for both RNA and protein analysis. Cells
were allowed to settle overnight (20-24 hours). Culture medium was removed, and 2 mL
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DMEM containing 0.2% FBS was added to each dish. After 24 hours of serum starvation,
two plates were harvested for RNA and protein analysis. This was time zero, and was used
as an untreated control. 2mL fresh DMEM containing 0.2% FBS ± TGF-β1 (10ng/mL; R&D
Systems, Inc.) was added to the remaining plates. A 10 ng/mL dose was used because others
had shown that it was an optimal dose for differentiating primary fibroblast cultures (149).
For initial analysis, cells were washed 1x in PBS and harvested 24, 48, and 72 hours post
treatment ± TGF-β1, to determine the best time point for analyzing SM α-actin protein
(Figure IV-1A). For all subsequent experiments, cells were analyzed 72 hours post
treatment ± TGF-β1.
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Figure IV-1. Myofibroblast time-course experiment. (A) Control myofibroblasts (n=4) were
differentiated from dermal fibroblasts through TGF-β1 treatment, and a time course
experiment was performed to determine the best timepoint for harvesting myofibroblasts for
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our study. Fibroblasts were plated at confluence. 20-24 hours after plating, fibroblasts were
serum-starved for 24 hours. Quiescent fibroblasts were either harvested at a zero-hour
timepoint or treated ± TGF-β1 and incubated for an additional 24, 48, or 72 hours. (B)
ACTA2 transcript levels (left panel) and SM α-actin protein expression (right panel) were
increased upon TGF- β1 stimulation. Transcript levels were normalized to GAPDH, and the
fold change relative to serum starved controls is shown. ACTA2 transcript levels were
slightly greater after 48 hours than 72 hours; however, the greatest amount of SM α-actin
protein was expressed at 72 hours, consistent with previously published results.
Representative immunoblots from three experiments are shown. Densitometry is a
composite from different fibroblast strains (right panel). Data are shown ± S.D. * p=0.05,
**p<0.01.
**************************************************************************
Protein isolation and immunoblotting
Protein was harvested in RIPA buffer containing 50 mM Tris-HCl pH 7.4, 1% NP40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 30µL/mL protease
inhibitor cocktail (Sigma), and phosphatase inhibitors (10 mM NaF and 1 mM Na3VO4).
Samples were incubated at 4ºC for 30 minutes and vortexed 3x periodically throughout the
incubation period, followed by centrifugation at 13,000 rpm for 30 minutes. Pellets were
discarded, and supernatant was quantified using a Bradford assay. Equal amounts (10µg) of
protein were boiled for 5 minutes in loading buffer, and loaded onto 4-20% acrylamide gels
(Bio-Rad). Protein was transferred to PVDF membranes and immunoblotted using standard
techniques. Briefly, membranes were blocked in 5% nonfat dry milk in TBS-T for 1 hour,
followed by primary antibody for either 1-2 hours at room temperature, or overnight at 4ºC.
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Secondary antibodies were used at a concentration of 1:5000 for one hour at room
temperature. Antibodies used are listed in Table 1 of Chapter II.

RNA isolation and quantitative gene expression analysis
RNA isolation and QPCR analysis were performed as previously described.

Immunofluorescence
Dermal fibroblasts were seeded onto 22mm glass coverslips at a density of 5,000
cells per coverslip and allowed to attach overnight. Myofibroblast differentiation was carried
out as described. 72 hours post TGF-β1 treatment, cells were fixed in 4% paraformaldehyde,
and immunofluorescent labeling was carried out as previously described for SMCs. Table 1
lists the antibodies and concentrations used.

Cell proliferation assays
Dermal fibroblasts were seeded in triplicate at a density of 20,000 per well, and were
allowed to attach overnight before serum-starving in DMEM containing 0.2% FBS. 24 hours
after serum deprivation, cells were treated ± TGF-β1 (10 ng/mL) and allowed to incubate for
72 hours, followed by incubation with BrdU reagent for an additional 24 hours. Cells were
fixed, and BrdU ELISAs were carried out according to the manufacturer’s instructions.
Assays were repeated three separate times (ACTA2 patients, n=9; controls, n=10). Statistical
significance was determined using Student’s t-tests.
For the IGF-1 receptor inhibitor and neutralizing antibody assays, fibroblasts were
plated in triplicate at 10,000 cells per well, serum-starved, and treated with TGF-β1 (10
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ng/mL) as described above. 72 hours post TGF-β1 treatment, cells were pre-treated for 30
minutes ± two different doses (0.1 µM and 1 µM) of PQIP (cis-3-[3-(4-methyl-piperazin-lyl)-cyclobutyl]-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-8-ylamine), a specific
IGF-1R inhibitor (OSI Pharmaceuticals, Inc.) before BrdU reagent was added (156). Cells
were also treated ± 200 nM IGF-1 as a positive control for inhibitor specificity. Cells were
incubated with BrdU reagent for 24 hours and fixed, and BrdU incorporation was quantified
through ELISA, according to the manufacturer’s instructions (Millipore, Billerica, MA).
Data are representative of three independent experiments. For the neutralizing antibody
assay, cells were plated in duplicate and treated ± α-IR3, an IGF-1R neutralizing antibody (2
µg/mL; Abcam) instead of PQIP. This concentration was chosen because concentrations of 1
µg/mL and 2.5 µg/mL have been shown inhibit proliferation in MCF7 cells and in metastatic
non-small cell lung cancer cells, respectively (157;158). Student’s t-tests were used to
determine statistical significance.

Analysis of IGF-1 secretion
To quantify IGF-1 secretion by ACTA2 mutant and control cells, myofibroblasts, an
IGF-1 ELISA (R&D Systems, Inc., Minneapolis, MN) was used. Cell culture supernatant
from 9 ACTA2 myofibroblast and 10 control myofibroblast samples were assayed, and the
IGF-1 ELISA was performed according to the manufacturer’s instructions. To better
concentrate the IGF-1 in the tissue culture supernatant, samples were concentrated using
Amicon Ultra centrifuge tubes (Millipore, Billerica, MA).

78

Results
Establishment of a myofibroblast model system
To determine the best method for myofibroblast differentiation, we tested two
different methods that were previously described in the literature. The first method involved
plating fibroblasts at low density and allowing them to grow to confluence, and the second
method involved treating confluent, serum-starved fibroblasts with TGF-β1 (148;149).
Plating fibroblasts at high vs. low density yielded variable and inconsistent results (data not
shown). Another disadvantage is that this method was time-consuming. Low density plated
cells took several weeks to reach confluency, and often did not survive well from being
plated so sparsely. In contrast, TGF-β1 treatment yielded far better and more consistent
results. One study showed that TGF-β1 treatment resulted in significantly increased SM αactin gene and protein expression as early as 24 hours, and another study showed that the
optimal amount of incubation time after TGF-β1 stimulation was 72 hours (149;151). We
tested several different timepoints to confirm the optimal incubation time in our fibroblast
system. SM α-actin mRNA was increased significantly 24 hours after TGF-β1 treatment,
and remained elevated at 48 and 72 hours (p<0.01). Immunoblot analysis showed that SM αactin protein expression was increased by 48 hours, with the greatest expression most
consistently at 72 hours (p<0.05; Figure IV-1B). A representative immunoblot from one out
of three independent controls is shown. Therefore, a 72-hour timepoint was used for the
remainder of experiments.
Dermal fibroblasts express SM α-actin in addition to other SMC contractile proteins
upon differentiation into myofibroblasts. Therefore we hypothesized that the myofibroblasts
would be a good model system for determining whether inducing SM α-actin expression had
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a proliferative effect on patients’ myofibroblasts. Assays for SM α-actin expression, actin
polymerization, and cell proliferation showed that myofibroblasts displayed similar
characteristics to SMCs and are a valid model system. Treatment of fibroblasts explanted
from controls (n=10) and from patients heterozygous for ACTA2 mutations (n=9) all showed
increased SM α-actin mRNA and protein expression at 72 hours following TGF-β1
treatment, consistent with published results (Figure IV-2A,B) (149).
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Figure IV-2. SM α-actin expression in ACTA2 mutant and control myofibroblasts. Both
ACTA2 mutant and control dermal fibroblasts significantly increase SM α-actin transcript
levels (A) and protein expression (B) 72 hours post TGF-β1 treatment (10ng/mL). Samples
with less of an increase in ACTA2 gene expression also displayed less SM α-actin protein
expression following TGF-β1 treatment. Gene and protein expression levels varied, with the
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most notable differences between R149 and R258 mutations. Error bars represent ± S.D.
QPCR data are normalized to GAPDH and are a composite of three experiments, and
representative immunoblots are shown. *p<0.05, **p<0.01.
**************************************************************************
Interestingly, the level of ACTA2 mRNA expression varied depending on the mutation, even
though all samples displayed a significant increase in mRNA expression upon TGF-β1
stimulation. The most marked difference was between R149C and R258H mutant samples.
SM α-actin protein expression was increased in all samples that were studied, and followed
a trend similar to that observed in mRNA levels.
Next, we used two different methods to determine whether SM α-actin filament
structure was disrupted in ACTA2 mutant myofibroblasts compared with controls:
immunofluorescent labeling of SM α-actin, and an ultracentrifugation assay to separate
polymerized vs. unpolymerized actin, followed by immunoblotting for SM α-actin.
Immunofluorescent staining showed that SM α-actin filaments were disrupted in patients’
myofibroblasts compared with controls (Figure IV-3A).
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Figure IV-3. SM α-actin polymerization is disrupted in ACTA2 mutant myofibroblasts.
Immunofluorescent labeling of total actin filaments (red) and SM α-actin (green) showed
normal total actin as well as α-actin filaments in control myofibroblasts, and these filaments
colocalized within the cell. In contrast, patients’ myofibroblasts lacked SM α-actin
filaments, and α-actin localized mainly in the perinuclear region, similar to results obtained
in ACTA2 explanted SMCs.
**************************************************************************
As a final step both in testing myofibroblasts as a model system and in confirming
that ACTA2 mutations lead to increased proliferation, we quantified the amount of DNA
synthesis in ACTA2 mutant vs. control myofibroblasts. 72 hours post TGF-β1 treatment, we
added BrdU reagent to the myofibroblasts and allowed cells to incubate an additional 24
hours. ACTA2 mutant myofibroblasts showed significantly faster proliferation, as assessed
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by BrdU incorporation, in culture than age and gender matched controls (Figure IV-4,
Table 3).

Figure IV-4. Increased proliferation in ACTA2 mutant myofibroblasts. (A) ACTA2 mutant
myofibroblasts (n=9) proliferated significantly more rapidly than controls (n=10) 72 hours
post treatment with TGF-β1. (B,C) Some variability was observed in the amount of
proliferation of R149C vs. R258H myofibroblasts. R149C mutant cells (n=3) proliferated
nearly twice as rapidly as matched controls, while R258H mutant cells (n=2) showed only a
marginal increase in proliferation. Data shown are a composite of three experiments, and
error bars represent ± S.E.M. *p<0.05, **p<0.01, ns = not significant.
*************************************************************************
These data further confirm our hypothesis that disruption in ACTA2 causes an increase in
proliferation. These data also indicate that myofibroblasts are a suitable model for studying
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the mechanisms driving increased proliferation due to ACTA2 mutations. However, similar
to the variability in SM α-actin expression, the amount of cell proliferation also appeared to
be dependent on the mutation. The largest difference was observed between myofibroblasts
harboring an R149C vs. R258H mutations (Figure IV-2, Figure IV-4). While R149C
mutant myofibroblasts proliferated nearly twice as rapidly as controls, R258H
myofibroblasts displayed only a marginal increase in proliferation that failed to reach
statistical significance.

Increased IGF-1 gene expression but not systemic IGF-1 production
We quantified IGF-1 gene expression in myofibroblasts to determine whether 1)
IGF-1 gene expression was increased similar to ACTA2 mutant SMCs, 2) whether sampleto-sample variations in the levels of IGF-1 expressions existed, and 3) whether TGF-β1
induced myofibroblast differentiation would be suitable for elucidating the role of IGF-1 in
ACTA2 SMC proliferation. IGF-1 gene expression was significantly increased in ACTA2
mutant myofibroblasts but not in controls upon TGF-β1 treatment. Similar to SM α-actin
expression and proliferation, the increase in IGF-1 expression varies based on the mutation
and cell strain. The R149C myofibroblasts expressed more IGF-1 than R258H
myofibroblasts (Figure IV-5).
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Figure IV-5. Increased IGF-1 gene expression in ACTA2 mutant myofibroblasts.
IGF-1 gene expression was significantly increased 72 hours post TGF-β1 treatment in four
out of six ACTA2 mutant myofibroblast samples tested (three out of four different ACTA2
mutations) compared with controls (n=5). The amount of IGF-1 overexpression was variable
in the patients, similar to ACTA2 gene expression results and appears somewhat proportional
to ACTA2 expression levels seen in Figure IV-3a. Notably, a stark contrast between IGF-1
expression in R149C vs. R258H mutant cells existed. The variable expression is similar to
results obtained in explanted ACTA2 SMCs. Data are normalized to GAPDH mRNA, and
error bars represent S.D. *p<0.05.
**************************************************************************
Since IGF-1 mRNA levels were increased, we made multiple attempts to quantify IGF-1
secretion by the myofibroblasts in culture. However, ELISAs performed on tissue culture
supernatant (R&D Systems, Inc.) failed to yield detectable levels of IGF-1, even after
centrifugation to concentrate media samples, and we were unable to determine whether the
increased IGF-1 mRNA corresponded with an increase in protein expression and secretion.
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Partial inhibitory effect of IGF-1R neutralizing antibodies or IGF-1R blocker on
proliferation
The goal of this study was both to establish a model cell system, and to utilize the
model to study the pathways driving proliferation in ACTA2 mutant cells. IGF-1 transcript
levels were increased in MYH11 SMCs, ACTA2 SMCs, and ACTA2 myofibroblasts, and
IGF-1 immunoreactivity was increased in MYH11 and ACTA2 aortic tissues. Since IGF-1
has known roles in promoting proliferation, we determined whether preventing IGF-1
signaling through the IGF-1 receptor would prevent the observed increase in proliferation.
To accomplish this, we used two different inhibitors: a small molecule inhibitor of IGF-1R
(PQIP), and an IGF-1R neutralizing antibody (α-IR3). Previously published data using PQIP
showed an IC50 within a nanomolar range, and that the IC50 for blocking cell proliferation in
a number of cancer cell lines was between 0.023-0.6 µM (156). Based on these data, we
used doses of 0.1 uM and 1 µM for our studies. PQIP blocked all IGF-1-induced
proliferation in both control and ACTA2 mutant myofibroblasts; however, the patients’
myofibroblasts continued to proliferate significantly more rapidly than the control cells even
after PQIP treatment (Figure IV-6A).
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Figure IV-6. ACTA2 mutant myofibroblast proliferation in vitro is not dependent on IGF-1.
(A) A specific IGF-1 receptor kinase inhibitor (PQIP; OSI Pharmaceuticals, Inc.) completely
prevents IGF-1 induced proliferation; however, in patients’ cells, proliferation is still
significantly greater than in controls after treatment with 1 µM PQIP, suggesting that
increased proliferation in these cells in vitro is not IGF-1 dependent. IGF-1 + PQIP
treatment served as a control to confirm inhibitor specificity. Data are representative of three
independent experiments. Error bars represent mean ± S.E.M. *p<0.05. (B) Similar results
were obtained using an IGF-1 receptor neutralizing antibody (α-IR3) at a concentration of
2µg/mL. Error bars represent mean ± S.E.M. *p<0.05.
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**************************************************************************
Similar results were obtained using an IGF-1R neutralizing antibody at a dose similar to
inhibitory doses used in two different cancer cell lines (Figure IV-6B). These data suggest
that at least in vitro, factors other than (or in addition to) IGF-1 are driving proliferation in
the ACTA2 mutant cells.

Discussion
The goals of this study were to develop a model for studying ACTA2 mutations, and
to use this model to determine whether the observed increase in proliferation is dependent
on IGF-1. ACTA2 mutant myofibroblasts express SM α-actin, have disrupted α-actin
filaments, increased proliferation, and increased IGF-1 expression compared with controls,
similar to explanted SMCs. These data all suggest that myofibroblasts are a good model for
studying the pathways leading to increased proliferation in the mutant SMCs.
Since IGF-1 is capable of driving both contractility and proliferation in SMCs, we
hypothesized that proliferation in these cells is dependent on IGF-1, and utilized the
myofibroblast model to address this question. However, the inability of the specific IGF-1
receptor inhibitor PQIP, an IGF-1 receptor neutralizing antibody, and additionally an ERK
inhibitor to completely block proliferation in these cells suggest that mechanisms other than
IGF-1 are driving proliferation in vitro. These mechanisms are likely complex, involving
input from multiple signaling pathways.
In addition to characterizing myofibroblasts as a model system and assessing
whether IGF-1 is driving proliferation in this system, we made some unexpected
observations, which may have clinical relevance. Some differences existed in SM α-actin
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and IGF-1 expression as well as proliferation in the mutant myofibroblasts. Based on the
consistency of the results from the controls, and the different clinical phenotypes observed
associated with R149C vs. R258H mutations, we hypothesize that these differences may
indicate slightly different disease mechanisms. R149C mutations are more frequently
associated with premature CAD, while R258C/H mutations are more associated with
premature stroke, along with Moyamoya disease. Some of the mutant myofibroblasts,
particularly those heterozygous for R258H mutations, showed less of an increase in ACTA2
upon TGF-β1 stimulation than other patients and controls, suggesting that either these
particular cell strains do not produce as much SM α-actin in response to TGF-β1
stimulation, or that some SM α-actin RNA and/or protein may be degraded. The same
myofibroblast samples (R149C vs. R258H mutant samples) also showed distinct differences
in proliferation after TGF-β1 treatment. Future studies will determine whether the
differences in R149C and R258H cells are clinically relevant, or are merely due to inherent
differences between primary fibroblast cell strains.
Myofibroblasts have proved useful as a model system, but they have several inherent
disadvantages. One drawback is that even after TGF-β1 stimulation, these cells are not fully
differentiated SMCs. Myofibroblasts express, but do not show SMC-specific splicing of,
SMC terminal differentiation markers (159). Also, myofibroblasts and SMCs contract using
different cellular mechanisms. Myofibroblasts contract mainly through Rho/ROCK
activation and subsequent inhibition of myosin light chain phosphatase (144). This pathway
leads to increased Ca2+ sensitization in SMCs, but contraction and maintenance of vascular
tone are also regulated by Ca2+ influx via stretch-dependent ion channels and voltage
dependent Ca2+ channels (160). Ca2+ binds to calmodulin and activates myosin light chain
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kinase. Phosphorylated myosin light chain allows for myosin to interact with actin and
generate contractile force (160). Also, contractile force generation is reversible in SMCs but
irreversible in myofibroblasts (144). Therefore, while myofibroblasts may help provide
insight into some cellular pathways, these cells may not be a good model system for
studying SMC contractility directly. In addition, the use of myofibroblast strains from
multiple individuals raises the possibility of genetic variability among patients and controls.
Another shortcoming of both the myofibroblast model and the SMCs used in Chapters II and
III is that all of these cells were grown in static culture, whereas SMCs in vivo are subjected
to mechanical strain due to pressure from blood flow. Finally, in the current study, the TGFβ1 treatment protocol created difficulties with accurately assessing IGF-1R activation. The
time frames for IGF-1R activation after myofibroblast differentiation through TGF-β1, the
length of the activation, and time of IGF-1 production are not known. Additionally, the
mechanism by which a specific contractile defect causes upregulation of IGF-1 is still not
known.
Despite these disadvantages, the myofibroblast model system still has some
advantages. The system is inducible in that the expression of SMC contractile genes can be
switched “on” and “off” based on a combination of the presence of TGF-β1 and the density
at which the cells are plated (149), An inducible model is advantageous because it has the
potential to reveal defects in the ability of SMCs to maintain a differentiated, contractile
phenotype in response to external stimuli. Current data obtained using the myofibroblast
model do not indicate that ACTA2 mutant SMCs have an impaired ability to maintain a
differentiated SMC phenotype, as shown by their robust upregulation of SM α-actin mRNA
and protein. However, this myofibroblast system is currently being utilized to show defects
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in SMC differentiation caused by TGFBR2 and COL3A1 mutations (Inamoto S. et al,
manuscript submitted; Dianna Milewicz, personal communication).
In conclusion, we have developed a myofibroblast model system that proved to be
useful in confirming a proliferative phenotype in ACTA2 mutant cells. However, due to the
inherent differences between myofibroblasts and SMCs, a SMC-specific model is needed for
further study of the specific mechanisms driving proliferation. Since actin filaments are
disrupted in both ACTA2 mutant SMCs and myofibroblasts, pathways that regulate both
actin polymerization and cell proliferation are excellent candidate pathways. Future work
will focus on 1) developing an SMC-specific cell culture model, 2) determining whether
pathways with a dual role in regulating actin polymerization and contractility drive
proliferation in this model and 3) confirming results in ACTA2 mutant SMCs. Additionally,
once these studies are completed, a transgenic or knock-in mouse model of Acta2 mutations
is needed to elucidate the specific role of increased proliferation in vivo. Although IGF-1
does not appear to be driving proliferation in vitro in R149C mutant myofibroblasts,
increased IGF-1 expression may still contribute to proliferation in vivo, and mouse models
of vascular injury and/or IGF-1 overexpression support this idea (110-113). Transgenic
mouse models with Acta2 mutations will be essential for addressing this question. These
mice could either be crossed with mice that overexpress or underexpress IGF-1, or IGF-1R
inhibitors could be used in vivo in these mice, to aid in determining whether IGF-1 drives
proliferation and is ultimately involved in disease pathogenesis.
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CHAPTER V
IDENTIFICATION OF PROLIFERATIVE PATHWAYS ACTIVATED BY LOSS OR
MUTATION OF ACTA2
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Background
While myofibroblasts have some advantages and usefulness as a model system, these
cells also possess a number of limitations that complicate the determination of proliferative
mechanisms (see Discussion, Chapter IV). Based on the myofibroblast studies, we
concluded that a SMC-specific model system is needed. In the absence of transgenic or
knock-in mouse models of Acta2 mutations, we considered three different model cell lines
or cell strains: transformed SMC lines transfected with vectors containing mutant ACTA2,
similarly transfected primary SMCs, or Acta2-/- SMCs.
Based on all of the available information about other cell strains, we chose to utilize
primary smooth muscle cells explanted from Acta2-/- mice as a model system. These cells
have several distinct advantages. First, unlike the myofibroblasts, they are genetically
uniform and should yield consistent results. Any differences between wildtype and Acta2-/SMCs are less likely to be due to extraneous genetic factors. Second, they are primary SMCs
rather than SMC lines that may have acquired other mutations or chromosomal alterations
since undergoing transformation. Third, these cells provide an ideal model for studying a
complete loss of SM α-actin filaments. Since α-actin filaments are disrupted in all of the
mutant cells that were assessed, we hypothesize that a complete loss of SM α-actin should
result in a similar phenotype and provide valuable insight into the mechanisms driving
proliferation and vascular occlusive disease associated with ACTA2 mutations in humans.
Acta2-/- mice were generated by Dr. Robert Schwartz and colleagues in 2000 by
inserting a vector containing the Acta2 gene with a Pol2neobpA cassette at the
transcriptional start site into embryonic stem cells, disrupting transcription of the Acta2
gene. Successfully targeted cells were injected into blastocysts of C57 mice to generate a
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chimeric mouse, and offspring were bred and genotyped for the presence or absence of
Acta2 (117). Major findings in the Acta2-/- mice included decreased contractility of isolated
aortic ring segments, decreased systolic blood pressure, inability to increase blood flow in
response to elevated body temperature, and impaired ability to raise blood pressure back to
normal levels after infusion with sodium nitroprusside, a compound that lowers blood
pressure. Acta2-/- mice showed a flattened appearance of elastic fibers in the aorta, which is
also indicative of decreased contractility. However, these mice were viable and the vascular
system developed normally. Other findings included increased mRNA and protein
expression of skeletal α-actin, presumably a compensatory response due to the complete loss
of SM α-actin. Endogenous skeletal α-actin overexpression, however, was unable to
completely restore contractility in the Acta2-/- vessels (117). Additionally, electron
microscopy revealed decreased formation of myosin thick filaments, providing evidence that
disruption of one element of the contractile apparatus leads to disruption of other
components as well (117).
In 2004, Zimmerman et al reported that Acta2-/- mice displayed decreased bladder
contractility in vitro and in vivo. Although this finding was significant in vitro, it was not
statistically significant in vivo, potentially because SM γ-actin is more abundant than SM αactin in the bladder. A third study showed that loss of Acta2 does not cause major
morphologic changes in retinal structure, but increased permeability of the blood-retinal
barrier, which resulted in decreased retinal function (161). A fourth study reported increased
kidney myofibroblast proliferation in Acta2-/- mice, using a unilateral ureteral obstruction
model of kidney injury (124). Acta2-/- mice showed increased fibrosis compared to wildtype
post-injury, as well as increased myofibroblast proliferation and procollagen-1 expression
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both in vitro and in vivo. These defects were rescued by transfection with an adenovirus
containing wildtype Acta2, providing evidence that the proliferation as well as the increased
injury response were due to an inability of the Acta2-/- kidney myofibroblasts to produce
smooth muscle α-actin (124). Additionally, FA proteins including phosphorylated FAK,
total FAK, paxillin, and vinculin were increased in Acta2-/- myofibroblasts (124). The
authors suggested that disruption of Acta2 leads to alterations in FAs, and that this
disruption may play an important role in disease development in their model (124).
However, the exact nature of the role of FAs in this disease process remains undefined.
From studies with the Acta2-/- mice, it is clear that both proliferation and SMC
contractility are altered due to the complete loss of a contractile protein. Others have
demonstrated that SM α-actin expression slows the growth of tumors and immortalized cell
lines, providing support for our argument that loss of contractile filaments can result in
either a loss or a gain of function depending on the location of the vascular bed (162;163).
Additionally, SM α-actin has a p53 response element within the promoter region, and is a
transcriptional target of p53 (147). We have shown that mutations that either disrupt or are
predicted to disrupt Acta2 polymerization lead to an increase in SMC and myofibroblast
proliferation, suggesting that total loss of Acta2 as well as deletion of Acta2 may drive
proliferation via similar cellular mechanisms (83). Therefore, SMCs explanted from Acta2-/mice should yield valuable insight into proliferative pathways in ACTA2 mutant SMCs.
As mentioned in the previous chapter, pathways and molecules that regulate both
SMC contractility and proliferation are excellent candidates for our study. One such
pathway is Rho/ROCK signaling. In SMCs, Rho is activated in response to contractile
agonists including endothelin-1 and Ang II that activate G-protein coupled receptors (160).
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Rho/ROCK signaling can also be activated in response to growth factor stimulation,
mechanical stretch, or through cell-ECM interactions (164). Rho activates ROCK, which
inactivates myosin phosphatase, allowing for myosin light chain to remain active
(phosphorylated) and increasing the cell’s sensitivity to calcium (160). Rho also plays an
essential role in driving actin polymerization by activating multiple effector proteins within
the cell. Increased actin polymerization in turn drives the expression of SMC-specific
markers including SM22, SM α-actin, SM myosin heavy chain, and calponin (165). In
addition to its roles in actin polymerization and SMC-specific gene expression, multiple
studies suggest that elevated Rho/ROCK signaling promotes SMC proliferation. Rho/ROCK
signaling leads to reduced p27 levels through increased Skp2 production, as well as elevated
cyclin D1 levels, resulting in cell cycle progression (166;167). Constitutively active Rho
promoted BrdU incorporation into NIH3T3 cells (168). HMG CoA reductase inhibitors
(statins) decreased the amount of Rho present at cell membranes and prevented Rho-induced
reduction of p27 levels, thereby reducing SMC proliferation (169). Although one study
reported that Rho activation did not induce SMC proliferation, this study was done on SMCs
from saphenous veins (170). Others have shown that arteries and veins are structurally and
functionally different, and that SMCs explanted from arteries vs. veins respond differently in
vitro, which could account for the disparity in results obtained (171). Overall evidence
suggests that Rho/ROCK activation is capable of driving SMC proliferation.
SRF-dependent regulation of SMC phenotypic switching may also contribute to the
increase in proliferation, and a general overview of SMC phenotypic switching is provided
in Chapter I. SRF acts as a molecular “switch” between contractile and growth-responsive
gene expression in SMCs, and that this switching is regulated in part through actin
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polymerization and nuclear localization of myocardin-related transcription factors (MRTFs)
(172;173). SRF phosphorylation at Ser162 leads to inhibition of myogenic genes, while still
allowing for expression of proliferative genes (174). Experimental evidence from multiple
sources shows that levels of unpolymerized actin (G-actin) within the cell control SRF
activation through regulation of MRTFs (175). There are two main classes of SRF cofactors:
MRTFs, which control muscle-specific differentiation, and TCFs that control growth factor
responsive genes (175). When G-actin levels increase in the cell, MRTF-A is exported from
the nucleus and binds to G-actin. MRTFs, which are normally found in the nucleus in
differentiated SMCs, are localized in the cytoplasm in fibroblasts but translocate to the
nucleus upon stimulation of RhoA-mediated actin polymerization (176). MRTFs and TCFs
compete with each other for binding to SRF (177). Removal of MRTF from the nucleus
increases the amount of SRF that binds to TCFs, allowing for greater smooth muscle cell
proliferation and growth. Activation of TCF/SRF transcription complexes is also promoted
by factors including mechanical stretch, vascular injury, and exogenous growth factor
stimulation, leading to increased ERK activation (175). Thus, changes in actin
polymerization coupled with vascular injury and/or the presence of excess growth factors
could potentially lead to a switch between MRTF/SRF and TCF/SRF mediated transcription
and subsequent proliferation.
Both Rho/ROCK and SRF mediated pathways are plausible candidates for driving
proliferation in ACTA2 mutant SMCs due to decreased SM α-actin polymerization.
However, this presents a potential dilemma in Acta2-/- SMCs, since there are no pools of
unpolymerized SM α-actin. Although conflicting evidence exists over whether SM α-actin
and other actin isoforms directly interact in SMCs, loss of a contractile protein may lead to
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disruption of cytoskeletal proteins as well. Therefore it is also possible that pools of other
unpolymerized actin isoforms in the Acta2-/- SMCs are increased, leading to proliferation
through either of the two mechanisms described.
A third candidate for study is focal adhesion (FA) dependent signaling, which
represents a group of pathways rather than a single pathway that regulate actin expression
and polymerization as well as cell proliferation (65). Multiple factors regulate the size,
specific composition, and the function of FAs, including the specific cell type being studied,
the ECM composition and stiffness, the activation state of associated integrins, and the
amount of contractile force generated by the cell (178). Integrin clustering is essential for
FA formation and is one of the early molecular events in this process (67). The focal
complexes formed by initial integrin clustering are short-lived structures, and contain αvβ3
integrin, talin, paxillin, phosphorylated proteins, and FAK (179). Early FAs contain zyxin as
well as greater quantities of the proteins recruited to focal complexes. Classical or “mature”
FAs are 2-6 µm in length, and contain little or no tensin or α5β1 integrin (180).
“Supermature” FAs are 8-30 µm long and contain increased amounts of vinculin and
paxillin, in addition to tensin and α5β1 integrin (180). In contrast to FAs, fibrillar adhesions
are mainly involved in organizing ECM and coordinating cell attachment to ECM. Fibrillar
adhesions contain large amounts of tensin and α5β1 integrin, but vinculin, paxillin, and αvβ3
integrin are almost entirely absent (180).
Following FA formation, SM α-actin filament formation is a critical step in the
process of FA development and maturation in myofibroblasts. Supermature FAs that are
connected to SM α-actin stress fibers are required for maximal contractile force generation
by myofibroblasts (180;181). Inhibition of α-actin expression during myofibroblast
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differentiation prevents FAs in these cells from developing into supermature FAs (182).
When SM α-actin is expressed, but depolymerization is induced, FAs are destabilized and
disassembled (181). Conversely, the length of the FAs formed regulates both the force
generated by the cell and the recruitment of SM α-actin to stress fibers (180).
In SMCs, FA regulation is vital for maintaining SMC contractile function (178).
FAK is an integral part of the FA complex, acting as a mechanosensor, a scaffold for
recruitment of other proteins to these complexes, and a regulator of FA turnover (67;68).
Knockdown of FAK expression in tracheal muscle strips resulted in decreased smooth
muscle contractile force generation (69). SM α-actin expression in response to external
forces is mediated in part through FAK activation (183). FAK signaling activates multiple
cellular pathways including Rho, Rac, PI3K, and Ras/ERK, and contributes to proliferation
and migration in adherent cells (184;185). Increased FAK signaling also leads to increased
proliferation and migration in multiple types of cancer (186). Expression of FRNK, an
alternative splice variant of the FAK gene that inhibits FAK activity, prevents SMC
proliferation (187-189). FAK is also overexpressed in diseased arteries and veins that
display intimal hyperplasia (190). In one study, FAK promoted SMC proliferation by
stabilizing Skp-2, an F-box protein that recognizes and degrades p27 (191). Thus, FAK is a
key molecule at FA sites, and activates multiple major pathways to regulate cell contractility
and proliferation.
Based on our data that actin filaments are disrupted in ACTA2 mutant cells, either a
Rho/ROCK dependent or SRF dependent mechanism, or a combination of both, may drive
increased SMC proliferation. Also, mutation or loss of SM α-actin is likely to alter FA
structure and function, disrupting multiple signaling pathways. We hypothesize that
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pathways with dual roles affecting both SMC contractility and proliferation are upregulated
in Acta2-/- SMCs, driving increased proliferation.

Materials and Methods
Mouse SMC isolation and culture
Acta2+/+ and Acta2-/- mice were anesthetized with 400mg/kg 2.5% Avertin (2-2-2
Tribromoethanol; Sigma-Aldrich). The ascending portion of the aorta distal to the heart and
just proximal to the innominate artery, and the descending portion of the aorta between the
left subclavian artery and the renal bifurcation were carefully removed. Adventitial fat was
dissected away using a scalpel and forceps. Aortas of two mice from each genotype were
pooled, and SMCs were explanted as previously described in Chapter II. Cells were cultured
in SmBm supplemented with growth factors (insulin, fibroblast growth factor, and epidermal
growth factor; Lonza), 20% FBS (Atlanta Biologicals), 1x antibiotic/antimycotic
(Invitrogen), 2mM L-glutamine, 20mM HEPES, and 1mM sodium pyruvate.
Cells were plated at 70-80% confluence (100,000 cells per 35mm dish, 350,000 cells
per 60mm dish, or 5,000 cells per 22mm round coverslip) and allowed to attach overnight in
complete media. Prior to protein or RNA isolation, cells were placed in lower-serum
medium without growth factors, and with 5% FBS, for 24 hours. For inhibitor assays, cells
were treated with inhibitor at the time of serum starvation, and were incubated with inhibitor
for 24 hours prior to harvesting cells.
For a subset of experiments, dishes and wells were coated with either fibronectin-1
(20 µg/mL; Sigma) or collagen IV (0.1 mg/mL; Sigma). Dishes and wells were allowed to
dry at room temperature overnight before cells were plated, and Collagen IV coated dishes
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were sterilized with UV light for 20 minutes prior to performing the experiment. Plating
SMCs on fibronectin-1 drives a more proliferative phenotype, and plating cells on collagen
IV drives a differentiated, contractile phenotype (192). We coated plates with both of these
matrices separately to determine whether driving either proliferation or differentiation had
differential effects on FAK activation and localization of FA components in the wildtype vs.
Acta2-/- SMCs.

Protein isolation and immunoblotting
Protein isolation and immunoblotting were carried out as previously described, with
the exception that phosphatase inhibitor cocktails I and II (10 µL/mL; Sigma-Aldrich) were
substituted for the 10 mM NaF and 1 mM Na3VO4. Antibodies and dilutions used are listed
in Table 1 in Chapter II.

RNA isolation and quantitative gene expression analysis
RNA isolation and quantitative PCR were performed using Trizol, RNeasy
purification, and Taqman gene expression assays as previously described in Chapter II. All
data were normalized to 18S and Gapdh separately, with similar results. Data shown in
graphs are normalized to 18S.

Microarray analysis
Duplicate samples of total RNA isolated from explanted descending aortic SMCs
from wildtype and Acta2-/- mice was used for study. An Agilent Bioanalyzer was used to
confirm RNA quality. After initial amplification, RNA was labeled and hybridized to an
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Illumina MouseWG-6 v2.0 beadchip. Illumina BeadStudio software was used to extract the
data and confirm data quality. Genes with a differential expression score of ≥ ± 30 (p<0.001)
were filtered for analysis. Ingenuity Pathways Analysis software was utilized to determine
whether major canonical signaling pathways were altered in the Acta2-/- SMCs compared
with controls (193). Genes with a twofold or greater change in expression and a p-value ≤
0.001 on the array were uploaded into the Ingenuity program, the altered genes were
compared against Ingenuity’s library of canonical pathways, and statistical significance was
automatically determined by the software using Fischer’s exact tests. Validation of selected
genes was performed using Taqman assays on an independent set of RNA samples, as
previously described.

Cell proliferation assays
Cells were plated 10,000 cells/well in triplicate. Preliminary experiments were
performed using different serum concentrations (0.2% and 5%) for different amounts of time
in low-serum media before BrdU was added (0 hours and 24 hours), in order to determine
optimal conditions for quantifying cell proliferation.
For treatment with inhibitors, cells were plated 5,000 cells/well (80-90% confluence)
and allowed to attach overnight. 20-24 hours after plating, cells were placed in SmBm
containing 5% FBS ± inhibitor. After 30 minutes of pre-treatment with inhibitor, cells were
incubated with BrdU reagent for 24 hours, and a BrdU ELISA was carried out as previously
described. The following inhibitors were used for study: U0126 (ERK), Y27632 (Rho
kinase), PF-532,278 (FAK), and PF-562,271 (FAK/Pyk2). Experiments were performed in
triplicate, and p-values were obtained using a Student’s t-test.
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Histology and immunofluorescence
Ascending and descending aortas from wildtype and Acta2-/- mice were isolated,
formalin-fixed and paraffin-embedded. Tissue sections were stained with H&E for analysis.
ImageJ software (NIH) was used to measure the circumference (C) around the inner layer of
the aortic wall, and aortic diameter was calculated by dividing C/π (77). Medial thickness
was also measured using ImageJ. Immunofluorescence was carried out as previously
described, with the following modifications: For phospho-FAK staining, cells were fixed in
ice cold 50/50 methanol/acetone for 5 minutes at -20C. Following fixation, coverslips were
rinsed 3x in PBS. For all other immunofluorescence, cells were fixed in 4%
paraformaldehyde in 0.1M phosphate buffer, as previously described. Cells were
permeabilized in PBS containing 0.2% saponin and 10% FBS for 10 minutes, and washed
3x in PBS prior to blocking and staining. 5% normal donkey serum in PBS was used for
blocking and for all antibody dilutions. Table 1 in Chapter II lists the antibodies and
concentrations used.

Transwell migration assays
Cells were plated 50,000 per well 0.2% FBS, in transwells containing membranes
with 8 µm pores (BD Biosciences). The final volume in each well was 500 µL, and cells
were plated in duplicate. Transwells were inserted into wells of a 24-well plate, containing
5% FBS + PDGF-B (10 ng/mL), with a final volume of 750 µL per well. Plates were
incubated for 6 hours. Transwells were washed in PBS, and cotton swabs were used to
gently remove non-migrated cells from the upper portion of each membrane. Cells were
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fixed in 4% paraformaldehyde for 10 minutes, washed 3x in PBS, stained with 0.5% crystal
violet for 10 minutes, washed 3x in PBS and allowed to dry overnight. Membranes
containing stained cells were cut from the transwell chambers and mounted onto slides using
Permount (Fisher). Five high-powered fields from each transwell membrane were
photographed by a blinded observer, and the cells per high-power field were counted.

Rho activation assay
A Rho pulldown assay was performed to determine whether more active RhoA was
present in the Acta2-/- SMCs. SMCs were seeded at 80-90% confluence in a T75 culture
flask and allowed to adhere overnight. Cells were serum-starved for 24 hours, and were
stimulated with complete media containing 20% FBS one hour prior to the assay. Assay
components were purchased from Cell Biolabs, Inc. (San Diego, CA). All work was
performed in a coldroom. Cells were washed 2x in PBS, and flasks were incubated on ice
1mL lysis buffer for 10 minutes and then scraped. Cell lysates were passed through a 27½
gauge needle to shear genomic DNA, and 60 µL of total lysate was set aside for protein
quantification and for immunoblotting of total RhoA. Lysates were centrifuges at 13,000 x g
for 10 minutes. Agarose beads conjugated to a Rho binding domain were resuspended, 40
µL of beads was added to each tube, and samples were incubated for 1 hour at 4ºC with
gentle shaking. Samples were centrifuged at 13,000 x g for 10 seconds, supernatant was
carefully removed and discarded, and samples were washed in 500 µL lysis buffer. The
wash was repeated a total of 3 times. After the final wash, the bead pellet was resuspended
in 2x reducing sample buffer, boiled for 5 minutes, and centrifuged at 13,000 x g for 10
seconds. Equal volumes of the pull-down assay supernatant, along with the total protein
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samples, were separated on a 10% polyacrylamide gel, transferred to a PVDF membrane,
and immunoblotted for RhoA.

Results
Characterization of the aortic phenotype in Acta2-/- mice
ACTA2 mutations cause aneurysms in humans; however, an aneurysm phenotype had
not been previously described in Acta2-/- mice. Therefore we wanted to determine whether
loss of SM α-actin in Acta2-/- mice also led to aneurysm formation. Ascending aortas from
Acta2-/- mice were significantly larger than wildtype at 10-12 weeks of age, indicating the
beginnings of aneurysm formation. Gross examination of the aortic tissue showed
enlargement of the ascending aortas in Acta2-/- mice compared with wildtype. No obvious
enlargement of the descending aorta was present (Figure V-1A).
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Figure V-1. Aortic aneurysms in Acta2-/- mice. Acta2-/- mice display ascending aortic
enlargement accompanied by increased proteoglycans and increased thickening and
cellularity in the vessel wall. (A) Upon gross examination, formalin-fixed ascending aortas
of 10-12 week old Acta2-/- mice appeared larger than age matched wildtype. There were no
apparent differences in the descending aorta. Scale bars represent 1.0mm. (B) H&E staining
(top two panels) revealed enlargement of the ascending aorta in Acta2-/- mice, along with
asymmetric thickening of the vessel wall and increased SMCs in the aortic media. Movat
staining (bottom panel) showed some proteoglycan accumulation (blue) in the Acta2-/aorta. Top panel is magnified 40x and middle and bottom panels are magnified 200x. Scale
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bars represent 500 µM. (C) Aortic diameter was measured using ImageJ analysis software,
and is significantly larger in 8-12 week old Acta2-/- mice (n=6) than age matched wildtype
(n=6). (D) Counting of medial SMCs showed increased SMCs in Acta2-/- aortas (n=6)
compared with wildtype (n=6). Cells in five high powered fields were counted for each
aortic tissue sample. Data for (C) and (D) are shown ± S.D. *p<0.05.
**************************************************************************
Histologic examination of ascending aortic tissue confirmed this enlargement (Figure 1B).
We used ImageJ software to measure the inner circumference of the aortic wall and then
calculated aortic diameter (Figure 1C). The diameter was significantly enlarged in 8-12
week old Acta2-/- mice (n=6) compared with age matched controls (n=6), and this change
was visibly apparent in the tissue in mice as young as 8 weeks.
Aortic aneurysms are associated with medial degeneration of the aorta, characterized
by proteoglycan accumulation and elastic fiber loss and fragmentation. We used Movat
staining to visualize ECM components in the aorta to determine whether medial
degeneration was present in the dilated aortas from Acta2-/- mice. Proteoglycan expression
was slightly increased in Acta2-/- compared with wildtype aorta (Figure V-1B). The aortic
wall also appeared asymmetrically thickened in Acta2-/- mice. To determine whether this
thickening was associated with increased numbers of SMCs in the medial layer, we counted
cells under high powered fields (400x; n=4 mice per genotype) and found that Acta2-/- aortas
had increased SMCs (Figure V-1D).
Overall, these data show a previously undescribed aneurysm phenotype in Acta2-/mice, accompanied by an increase in the number of SMCs present in the vascular wall, and
minimal changes typical of medial degeneration. Based on these data and on previously
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published data, Acta2-/- mice are likely to be a suitable model for our studies of SMC
proliferation in association with aneurysm formation.

Increased proliferation and migration in Acta2-/- SMCs
Previous studies reported increased proliferation in Acta2-/- renal myofibroblasts
(124). Based on these data and on our data showing increased proliferation in ACTA2 mutant
SMCs and myofibroblasts, we hypothesized that the Acta2-/- SMCs would also demonstrate
increased proliferation and would provide a suitable model system. Our initial experiments
to test culture conditions showed that serum deprivation using 5% FBS at the time of BrdU
incubation yielded the best and most consistent results. Therefore, this experimental setup
was used for the remainder of the cell proliferation assays. Similar to ACTA2 mutant SMCs
and myofibroblasts, Acta2-/- SMCs explanted from both the ascending and descending aorta
proliferate significantly more rapidly than wildtype in vitro (Figure V-2A).
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Figure V-2. Increased proliferation and migration in Acta2-/- SMCs. (A) SMCs explanted
from both the ascending and descending aortas of Acta2-/- mice proliferated significantly
more rapidly than wildtype. (B) Transwell migration assays showed that Acta2-/- SMCs in
0.2% FBS migrated more rapidly toward a gradient of 5% FBS + 10ng/mL PDGF than
wildtype. The experiment was performed in duplicate wells and repeated three times.
Results were quantified by counting the number of migrated cells per high powered
microscope field on the transwell membrane. Five separate fields were counted per sample,
and representative images of cells on the transwell membrane are shown. Interestingly,
Acta2-/- SMCs display slightly elongated morphology compared with wildtype. Error bars
represent ± S.E.M. *p<0.05
**************************************************************************
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Since increased migration was also described in Acta2-/- myofibroblasts, we performed
transwell migration assays to determine whether Acta2-/- SMCs also displayed increased
migration (124). We used a transwell assay rather than a scratch or wounding assay because
it allowed for assessment of cell migration in response to a chemotactic gradient (10 ng/mL
PDGF-B). However, one disadvantage was that we were unable to monitor changes in cell
shape during migration. Descending Acta2-/- SMCs migrated more rapidly than wildtype
toward the PDGF-B gradient (Figure V-2B). These data indicate that Acta2-/- SMCs are a
suitable model for studying SMC proliferation in response to a contractile protein defect,
and suggest that increased SMC migration may be important as well.

ROCK and ERK inhibitors partially but not completely block proliferation
Based on the role that Rho/ROCK plays in actin polymerization and also in SMC
proliferation, we hypothesized that Rho was overactivated in Acta2-/- mice, in response to
the inherent contractile defect. Treatment of Acta2-/- SMCs with a ROCK inhibitor, Y27632,
resulted in decreased proliferation in both Acta2-/- and wildtype SMCs, although only the
decrease in Acta2-/- SMC proliferation was significant (Figure V-3A).
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Figure V-3. Rho and ERK inhibitors partially block Acta2-/- SMC proliferation. (A)
Treatment of SMCs with either a Rho kinase inhibitor (Y27632) or an ERK inhibitor
(U0126) caused a significant decrease in proliferation in Acta2-/- SMCs but failed to
completely block the proliferation compared to wildtype. For the ERK inhibitor, DMSO was
added to the untreated cells to control for the DMSO present in the inhibitor solution. Data
shown are a mean of three observations and error bars represent ± S.D. *p<0.05. (B) A Rho
pulldown assay failed to show a difference in GTP-bound RhoA in Acta2-/- mice compared
to wildtype. Additionally, p27 expression remained the same. Since p27 is degraded in
response to RhoA activation, these data suggest that a Rho/p27 mediated mechanism is not
likely driving proliferation.
**************************************************************************
Since doses of 10, 20, and 30 µM were used to block Rho activation and proliferation in
TSC2-/- cells, we treated Acta2-/- SMCs with the same doses (194). However, even the
highest dosage of 30 µM failed to completely prevent increased proliferation. Since the
ROCK inhibitor partially inhibited proliferation, we used a Rho pulldown assay to determine
whether RhoA activation was increased. We did not observe any difference in Rho activity
between the Acta2-/- and wildtype SMCs (Figure V-3B). Since small changes in RhoA can
be difficult to detect using this assay, we immunoblotted for p27, since it is known to be
degraded in response to Rho activation (169). However, p27 levels were not altered.
Together, these data suggest that Rho/ROCK activation plays a role in overall SMC
proliferation, but is not the main pathway driving proliferation in the Acta2-/- SMCs.
We also hypothesized that a switch between SRF/MRTF and SRF/TCF mediated
gene expression, in concert with growth factor stimulated ERK activation, might be driving
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proliferation. We labeled SMCs with MRTF-A to determine subcellular localization. We
expected to find increased cytoplasmic localization; however, immunofluorescent labeling
failed to yield interpretable results. QPCR analysis of c-fos, a gene known to be induced by
SRF/TCF, showed that steady state expression levels were not increased in the Acta2-/SMCs (not shown). We hypothesized that an increase in G-actin leads to increased
cytoplasmic localization of MRTFs. We also hypothesized that in the complete absence of
SM α-actin, β-actin filaments would be disrupted. However, immunofluorescent labeling of
β-actin did not reveal an appreciable difference in β-actin filaments between the wildtype

and Acta2-/- SMCs. Overall, we were unable to conclusively determine whether SRF
mediated signaling contributes to the proliferation. Since IGF-1 was increased in ACTA2
mutant SMCs and myofibroblasts, and is also known to activate ERK signaling, we
hypothesized that IGF-1 along with ERK activation would be increased and potentially drive
proliferation. However, in contrast to ACTA2 mutant SMCs and myofibroblasts, we did not
find any change in IGF-1 gene expression in Acta2-/- SMCs, suggesting that either other
growth factors or other cellular pathways may be more important in the proliferative
phenotype. Similar to the ROCK inhibitor, an ERK inhibitor, U0126, partially blocked but
did not fully prevent increased proliferation in the Acta2-/- SMCs (Figure V-3A).
Additionally, untreated Acta2-/- SMCs failed to show consistent increases or decreases in
phosphorylated ERK (not shown). Taken together, these data suggest that although ERK
activation may drive part of the increased proliferation, additional cellular pathways are
involved.
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Gene expression analysis in Acta2-/- SMCs
We used Ingenuity Pathway Analysis software to determine whether canonical
pathways were altered in the Acta2-/- SMCs, leading to proliferation. Interestingly, the top
canonical pathway identified by Ingenuity was Hepatic Fibrosis/Hepatic Stellate Cell
Activation (p = 5.72E-10). Hepatic stellate cells are capable of transitioning to a
myofibroblast-like proliferative phenotype and producing excessive ECM proteins
(particularly collagen) in response to injury, and both the proliferation and ECM production
are dependent on FAK signaling (195). Since both FAK and procollagen 1 expression were
increased in Acta2-/- renal myofibroblasts, we would expect to find increased collagen
production as well as FAK in the Acta2-/- SMCs (124). Since FAK is an integral part of FAs,
we also looked for alterations in any genes known to be associated with focal adhesions
(196). We found alterations in genes associated with ECM production and FAs, as well as
genes associated with the SMC contractile complex and cell adhesion. A summary of these
genes is listed in Table 4.
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Table 4. FA, ECM, adhesion, and contractile genes altered in Acta2-/- SMCs.
Contractile apparatus
Gene

Protein name

Focal adhesion-related genes
Fold change

Gene

Protein name

Fold change

Actg2*

actin, gamma 2, smooth muscle,
enteric

24.78

Itga5

integrin alpha 5 (fibronectin
receptor alpha)

2.24

Myh11*

myosin, heavy polypeptide 11,
smooth muscle

8.44

Itga11

integrin, alpha 11

3.98

Smtn

smoothelin

2.26

Itgb4

integrin beta 4, transcript variant 2

4.83

Tagln

transgelin

3.81

Lims2

LIM and senescent cell antigen like
domains 2 (pinch2)

3.58

Tpm2

tropomyosin 2, beta

2.12

Fhl2

four-and-a-half LIM domains 2

3.25

Tpm1

tropomyosin 1, alpha

1.58

Palld

palladin

3.43

Acta2*

actin, alpha 2, smooth muscle

-8.96

Bmx

BMX non-receptor tyrosine kinase
(Etk)

3.06

Csrp1

cysteine and glycine-rich protein 1

3.01

Fold change

Flnb

filamin B

2.15

elastin

8.09

Cav1

caveolin, caveolae protein 1

1.96

procollagen, type XII, alpha 1

7.99

Vim

vimentin

1.77
1.65

Extracellular Matrix
Gene
Eln
Col12a1

Protein name

Col18a1

procollagen, type VIII, alpha 1

7.03

Rac3

RAS-related C3 botulinum
substrate 3

Col6a3

procollagen, type VI, alpha 3

6.76

Nck2

non-catalytic region of tyrosine
kinase adaptor protein 2

1.61

Col3a1

procollagen, type III, alpha 1

4.36

Sorbs1

ponsin

1.58

Col15a1

procollagen, type XV

3.88

Actn1

actinin, alpha 1

1.57

Col7a1

procollagen, type VII, alpha 1

3.57

Tgfb1i1

TGF-β1 induced transcript 1

1.49

Col6a2

procollagen, type VI, alpha 2

2.95

Sdcbp2

syntenin 2

1.44

Col5a1

procollagen, type V, alpha 1

2.79

Rapgef1

Col10a1

procollagen, type X, alpha 1

2.75

Ptk2b

Col4a1

procollagen, type IV, alpha 1

2.51

Itgb1bp1

Col4a2

Rap GEF 1

1.42

protein tyrosine kinase 2 beta

1.37

integrin beta1 binding protein 1

1.36

procollagen, type IV, alpha 2

2.38

Vcl

fibronectin 1

2.08

Parva

Col6a1

procollagen, type VI, alpha 1

2.01

Zyx

zyxin

-1.30

Col1a2

procollagen, type I, alpha 2

1.94

Ppfia1

liprin

-1.46

Col5a2

procollagen, type V, alpha 2

1.52

Sdcbp

syntenin 1

-1.54

Col16a1

procollagen, type XVI, alpha 1

1.33

Vil2

ezrin

-1.57

Col4a5

procollagen, type IV, alpha 5

-1.36

Pfn2

profilin 2

-1.58

Col8a1

procollagen, type VIII, alpha 1

-1.75

Tln2

talin 2

-1.64

Col4a6

procollagen, type IV, alpha 6

-5.62

Prkcm

Col28a1

collagen, type XXVIII, alpha 1

-6.26

Fn1

Cadherins

1.22
-1.25

polycystin-1

-1.69

Pfn2

profilin 2

-1.78

Pak4

p21 protein-activated kinase 4

Gene

Protein name

Cdh5

cadherin 5 (VE-cadherin)

6.15

Gene

Cdh13

cadherin 13 (T-cadherin)

4.83

Pip5k1b*

Pcdh9

protocadherin 9

-3.79

Srpx2

Pcdh21
Gm1010

protocadherin 21
cadherin-like 26

-3.80
-3.99

cadherin 3 (P-cadherin)

-4.77

Cdh3

vinculin
parvin, alpha

Fold change

-2.42

Other
Protein name

Fold change

PIP5 kinase, type 1 beta

13.49

Sushi repeat protein X-linked 2

11.40

*denotes validation by Q-PCR
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Table 4. FA, ECM, adhesion, and contractile genes are altered in Acta2-/- SMCs.
Acta2-/- SMCs displayed increased ECM production, including elastin, fibronectin 1, and
fifteen different collagen genes. Multiple FA-associated and adhesion genes are also altered,
suggesting that these SMCs are fibrogenic and have altered adhesive properties. The fold
change listed is the relative expression level in Acta2-/- SMCs compared with wildtype. An
asterisk denotes validation via QPCR.
**************************************************************************
FAK gene expression was unaltered, and this was confirmed via QPCR; however,
fifteen different collagen genes were upregulated, and twelve of these were increased by
twofold or more. Only four collagen genes were downregulated, and two were decreased by
more than twofold. Elastin and fibronectin also were upregulated eightfold and twofold,
respectively. Since ECM overproduction is a characteristic feature of de-differentiated
SMCs and ECM accumulation is evident in the intimal lesions in humans, we hypothesized
that Acta2-/- SMCs exhibit a de-differentiated phenotype. However, expression of multiple
terminal SMC differentiation markers were either unaltered or were increased in the Acta2-/SMCs. Out of these genes, we validated increased expression of Myh11 and Actg2. Calponin
1 is an additional marker of differentiated SMCs: although this gene was not listed in the
array results, QPCR analysis showed that this gene was also increased in Acta2-/- SMCs. All
of these gene expression data suggest a differentiated, contractile SMC phenotype rather
than a de-differentiated phenotype. Additional evidence that these SMCs are not dedifferentiated is S100A4 expression. S100A4 is a marker for de-differentiated SMCs in
culture, but was not increased in Acta2-/- SMCs (197). The most highly upregulated gene on
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the array was Actg2, encoding SM γ-actin, and was increased 24.78-fold. These data are
consistent with SM γ-actin increases reported by Takeji et al (124).
A number of genes encoding proteins that are known to be associated with FAs were
altered in the Acta2-/- SMCs. Out of these alterations, twenty-two genes were upregulated,
and nine of these genes were increased by twofold or greater. Ten genes were
downregulated, and only one gene was downregulated by more than twofold. Of note,
several integrin receptor levels are increased in the Acta2-/- SMCs: β4, α5, and α11. Several
kinases, either associated directly or potentially associated with FAs, were also increased,
including Etk, FAK2, and Pip5k1b. Although not directly localized to FAs under normal
conditions, Pip5k1b has the potential to localize to the cell membrane when overexpressed
(198). Also, Pip2 production within the cell has the potential to influence and regulate FA
dynamics (198). Therefore, although not included in the final count of upregulated FArelated genes, Pip5k1b may be relevant for the study of FA alteration in the Acta2-/- SMCs.
Other adhesion-related genes were also altered in Acta2-/- SMCs. Cadherin 13 was
upregulated 4.83-fold and is of particular interest because this protein, unlike other
cadherins, has anti-adhesive properties, and its expression is associated with increased cell
migration and proliferation, as well as alterations in FA localization with the cell (199).
SMCs from Acta2-/- mice are generally more elongated in culture, and this change is
particularly evident in the descending SMCs (Figure V-2B). The elongated phenotype,
coupled with overexpression of cadherin-13, is consistent with reports of cells that have
been transfected with cadherin-13 or that have been plated on a cadherin-13-containing
substrate(199). Srpx2 (Sushi repeat containing protein, X-linked 2) gene expression was also
highly upregulated (11.4-fold). Recently, this protein was found to increase FAK activation
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in gastric cancer (200). Collectively, these microarray data suggest that FAs are altered in
Acta2-/- SMCs.

Focal adhesions are altered in Acta2-/- SMCs
Vinculin is a marker for mature FAs, and tensin is a general marker for fibrillar
adhesions. Since tensin and vinculin colocalization is an indicator of supermature FAs in
differentiated myofibroblasts, we double-immunolabeled Acta2-/- and wildtype SMCs with
these markers to determine if FA maturation was altered in the Acta2-/- SMCs (180). Tensin
immunofluorescence showed a small amount of tensin-vinculin colocalization in the
wildtype compared to Acta2-/- SMCs, possibly due to vinculin localization more at the cell
periphery in the Acta2-/- SMCs than in wildtype (Figure V-4A).
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Figure V-4. Altered localization of FA components in Acta2-/- SMCs.
(A) Since tensin and vinculin colocalize in supermature FAs, we double labeled Acta2-/- and
wildtype SMCs with tensin and vinculin. A small amount of tensin and vinculin
colocalization is present in the wildtype but not Acta2-/- SMCs, possibly due to vinculin
localization more at the cell periphery in Acta2-/- SMCs. (B) Vinculin-containing FAs
(green) are localized more to the cell periphery in Acta2-/- SMCs than in wildtype SMCs.
Results are representative of cells plated on collagen IV coated, fibronectin-1 coated, or
uncoated coverslips, from two separate experiments. This staining pattern can also be seen
in panel A. Staining of actin stress fibers (red) confirmed vinculin localization at adhesion
sites at the ends of the actin fibers. Since vinculin is a definitive marker for FAs, these data
confirm that FAs are altered in Acta2-/- SMCs compared to wildtype. (C) Since zyxin
localizes to FAs but translocates to actin stress fibers or to the nucleus when cells are
exposed to mechanical force, we immunofluorescently labeled SMCs with zyxin (green) and
observed consistent alterations in zyxin staining patterns. In wildtype SMCs zyxin was
localized to some adhesion sites at the cell periphery, and also localized in a punctate pattern
within the perinuclear region of the cell. In Acta2-/- SMCs, zyxin exhibited a distinct, tubular
staining pattern that was neither perinuclear nor localized to actin stress fibers. The
subcellular structure(s) that zyxin is localizing to in these cells has not yet been determined;
however, together these data support that FAs are altered in Acta2-/- SMCs. Cells shown
were plated on fibronectin-1; similar and consistent results were obtained for cells plated on
collagen IV and on uncoated coverslips.
**************************************************************************
Since vinculin is a widely used marker for FAs, we double immunolabeled cells with
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vinculin along with phalloidin, so that both FAs and actin filaments within the cell could be
visualized. We observed that vinculin is consistently localized more to the cell periphery in
the Acta2-/- SMCs than in wildtype (Figure V-4A,B). Similar localization patterns have been
observed in fibroblasts that lack integrin-linked kinase (another FA-associated protein) and
in SMCs that overexpress cadherin 13 (199;201).
Zyxin localizes to mature FAs, but also acts as a sensor and transducer of mechanical
force in SMCs and moves from the FAs to the actin filaments with the application of
mechanical force to cells (202;203). Since Acta2-/- mice have decreased aortic contractility,
we hypothesized that localization of a mechanosensitive FA marker would be altered in
these cells compared with wildtype. Whereas in wildtype mice zyxin was present in FAs at
the cell periphery and in more punctate patterns in the perinuclear region, in Acta2-/- SMCs
zyxin was formed into long, tortuous rodlike structures that do not localize with the β-actin
filaments or in the nucleus (Figure V-4C). Based on these studies, zyxin localization is
altered in the Acta2-/- SMCs but the etiology of the rod shaped structures that appear with
zyxin staining in the null cells has not been determined.
Fibronectin-coated coverslips were used for all of the immunofluorescence studies
for several reasons: 1) fibronectin drives FA formation in SMCs and therefore should
highlight any problems with FA formation in the Acta2-/- SMCs, and 2) the most consistent
inhibition of cell proliferation with two different FAK inhibitors (described below) was
obtained using cells plated on fibronectin. While all results shown are from SMCs plated on
fibronectin coated coverslips, SMCs plated on both collagen IV and uncoated coverslips
produced similar results.
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Since FAK is important for scaffolding as well as regulating FA formation and
turnover, we immunostained and immunoblotted for phosphorylated FAK. Immunoblotting
showed a slight increase in FAK in the descending but not the ascending SMCs, and
immunoblot results from the descending SMCs are shown in Figure V-5A.
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Figure V-5. FAK dependent proliferation in Acta2-/- SMCs. (A) Immunoblotting showed
that pY397 FAK and total FAK are increased in descending Acta2-/- SMCs when plated on
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uncoated or collagen IV coated matrices. The difference was less apparent in cells plated on
fibronectin-1. (B) pY397 FAK is localized more to FAs at the cell periphery in Acta2-/SMCs. This was consistent for both ascending (top two panels) and descending (bottom two
panels) SMCs. Additionally, pY397 FAK staining at FAs appears more intense in Acta2-/SMCs than in wildtype. (C-E) The FAK inhibitor PF-562,271 completely blocked increased
proliferation in Acta2-/- SMCs plated on uncoated plates (C), and fibronectin-1 or collagen
IV coated plates (D and E, respectively). A second FAK inhibitor, PF-532,278, completely
blocked proliferation on fibronectin-1 coated surfaces but not uncoated or collagen IV
coated surfaces (not shown). Together, these data indicate that Acta2-/- proliferation is
dependent on FAK signaling. Experiments were performed in triplicate, and data are shown
± S.D. *p<0.05, **p<0.01, ns = not significant.
**************************************************************************
Densitometry did not yield a statistically significant difference in increased FAK between
the Acta2-/- and wildtype SMCs. However, immunofluorescent staining revealed alterations
in the localization of phosphorylated FAK in Acta2-/- compared with wildtype SMCs.
Phosphorylated FAK is concentrated at focal adhesions at the cell periphery (Figure V-5B).
Although FAK can be autophosphorylated within the cytoplasm, FAK that is actively
signaling is only found in FAs (204). Therefore, the stronger localization of phosphorylated
FAK at the cell periphery in FAs in Acta2-/- SMCs suggests that FAK signaling is increased,
even though total levels of FAK are not dramatically altered.

Multiple FAK inhibitors block increased proliferation in Acta2-/- SMCs
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SMCs plated on collagen, fibronectin, or uncoated 96-well plates were treated ±
either of two FAK inhibitors, PF-532,278 or PF-562,271. We initially chose to use PF532,278 because of its availability and specificity (205). This inhibitor completely blocked
proliferation of the Acta2-/- SMCs plated on fibronectin-1 but only partially blocked
proliferation in cells plated on collagen IV or uncoated plates (data not shown). To confirm
the results, we obtained PF-562,271, a molecule that is currently in clinical trials for
treatment of cancer (206). In contrast to the first FAK inhibitor, PF-562,271 completely
prevented increased proliferation in Acta2-/- SMCs plated on all of the three matrices.
Results are shown for fibronectin-plated cells treated ± PF-562,271 (Figure V-5C). Similar
results were obtained for cells plated on uncoated or fibronectin-1 coated matrices ± PF562,271, and also for cells plated on fibronectin-1 coated matrices ± PF-532,278 (not
shown). Together, these data suggest that FAK dependent signaling is at least in part driving
the observed proliferation in Acta2-/- SMCs.

Discussion
Acta2-/- mice are the first mouse model of aortic disease caused by disruption of a
SMC-specific contractile protein. Additional characterization of these mice and in vivo
quantification of the increases in aortic diameter should confirm this finding. Aortas in mice
as young as 8 weeks are enlarged compared with wildtype, and aortas were previously
shown to display decreased contractility, suggesting that these mice are a good model for
studying aneurysm formation due to an inherent SMC contractile defect. Since other existing
mouse models of aortic aneurysms focus on the contribution of TGF-β1 signaling and/or
extracellular matrix proteins, a mouse model with an SMC contractile defect represents a

123

unique opportunity to define novel pathways leading to aneurysm formation. Establishment
of this model is important for our understanding of thoracic aortic disease. The FBN1 mouse
recapitulates the aneurysms found in MFS, which involve initially the sinuses of Valsalva.
In contrast, aneurysms in patients with ACTA2 mutations are the more common form of
aneurysm, sparing the sinuses of Valsalva and involving the ascending aorta. These are also
the type of aneurysms that form due to chronic hypertension. The Acta2-/- mice showed
enlargement of the ascending aorta and should be particularly useful in determining the
differences in pathogenesis between aneurysms due to MFS and aneurysms caused by either
hypertension or ACTA2 mutations.
Increased SMC numbers in aortic tissue indicate that Acta2-/- mice are a good model
for studying the contribution of cell proliferation to aortic aneurysm formation as well. We
observed increased SMCs and expansion of the vessel wall were found prior to significant
medial degeneration in Acta2-/- mice. This is in contrast to aneurysm formation in MFS
mouse models, where medial degeneration occurs at an early stage and increased SMCs in
the medial layer are not observed (10). The observation that one of the initial pathologic
features in the Acta2-/- aortas is SMC proliferation suggests a potential role for proliferation
in aneurysm formation in this mouse, and raises the question of whether SMC proliferation
drives aneurysm formation in ACTA2 mutant aortas. Recent pathologic examination of
aortic tissues from patients with an exceptionally severe ACTA2 mutation, R179C, support
this idea (Dianna Milewicz, personal communication). Aneurysmal tissue from these
patients showed minimal medial degeneration coupled with subintimal SMC hyperplasia.
Through study of Acta2-/- SMCs, we have made several important observations:
alterations in expression of FA-associated genes, peripheral localization of FAs, increased
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pFAK localization in FAs, and increased proliferation that is dependent at least in part on
FAK. Altered vinculin localization in Acta2-/- SMCs provides evidence of disruption of both
FAs and contractile force generation by the cell. Vinculin incorporation into FAs is required
for generation of force by SMCs and is thought to be proportional of the amount of force
being generated by the cell (207). This idea is consistent with the decrease in vinculincontaining adhesions across the cell body of Acta2-/- SMCs, and also agrees with previously
published data that Acta2-/- aortas (and by implication also, Acta2-/- SMCs) have decreased
ability to contract in vivo (117). Further, the stability of focal complexes at the cell
periphery may be altered, and future work will determine whether FA turnover is increased
in Acta2-/- compared to wildtype SMCs. The increased migration observed in the Acta2-/SMCs is consistent with a rapid rate of FA assembly and disassembly (179).
Changes in localization of zyxin suggest that Acta2-/- SMCs have an altered ability to
transduce force signals. Zyxin is a mechanosensitive component of FAs that is translocated
to either actin stress fibers or to the nucleus when the cell is placed under mechanical stress,
and may also act to reinforce the cell cytoskeleton (202;203). Future work will identify the
subcellular structure that zyxin is localizing to within Acta2-/- SMCs.
In addition to the observed alterations in other FA proteins, FAK expression and
localization is also altered. In the descending SMCs, FAK expression is increased, consistent
with data from Acta2-/- myofibroblasts (124). However, unlike the myofibroblasts, this
increase was not nearly as pronounced, and was not statistically significant. This could be
due to inherent differences between myofibroblasts and SMCs.
Similar to patterns of vinculin immunofluorescent staining, phosphorylated FAK is
localized more at FAs at the cell periphery in Acta2-/- SMCs compared to wildtype. Since
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these cells also migrate more rapidly in culture, these data are consistent with other reports
of FAK localization to peripheral FAs during cell migration (204). FAK is found primarily
at FAs but can be localized in the cytoplasm or nucleus as well. Phosphorylated FAK
(Y397) is found mainly at FA sites along the cell periphery, but can also be
autophosphorylated while still in the cytoplasm and/or localized to FAs further away from
the edge of the cell (204). Transfecting cells with a C-terminal fragment of FAK displaced
FAK from FAs and reduced proliferation and migration, showing that localization of FAK
to FAs is required for fully functional signaling (185). Thus, despite the fact that
immunoblotting did not reveal large differences in FAK phosphorylation, the
immunofluorescence data show more FAK localization at the cell periphery, suggesting that
FAK is altered in Acta2-/- SMCs.
Multiple FAK inhibitors were successful in blocking proliferation in Acta2-/- but not
wildtype SMCs plated on fibronectin-1, suggesting that Acta2-/- proliferation is at least in
part dependent on FAK. However, both of the kinase inhibitors used target FAK as well as
several other nonspecific targets (205;206). PF-562,271 also inhibits Pyk2 (FAK2), which
also localizes to the cell membrane and can drive proliferation when activated (208).
Although Pyk2 is not nearly as highly expressed as FAK in SMCs, Pyk2 mRNA expression
is marginally increased (1.37-fold) in Acta2-/- SMCs. This increase in expression has not yet
been validated, and the role of Pyk2 in Acta2-/- SMC proliferation remains unknown. PF562,271 appears to be a more potent inhibitor of Pyk2 than PF-573,228, which may explain
why only partial inhibition of proliferation was achieved on uncoated and collagen-coated
matrices using this inhibitor. Thus, while localization of phosphorylated FAK is clearly
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altered in the null SMCs, we cannot rule out the possibility that the complete inhibition of
proliferation is due to the dual inhibition of FAK and Pyk2 (205;206).
Microarray analysis revealed increased SMC contractile gene expression, increased
collagen gene expression, and alterations in a number of FA-associated genes. Since Acta2-/SMCs were more proliferative and showed increased levels of ECM genes, we expected
these cells to have a more de-differentiated phenotype. However, contrary to our
expectations, Acta2-/- SMCs had increased expression of multiple markers of mature SMCs,
including Myh11 and Cnn1. Additionally, these SMCs did not display increased expression
of S100A4, a marker of dedifferentiated, proliferative SMCs. These data indicate that
Acta2-/- SMCs are proliferating in the absence of phenotypic switching, and agree with other
observations that contractile and synthetic SMCs do not necessarily represent two mutually
exclusive SMC phenotypes (56).
Multiple genes on the microarray suggest that FAs and potentially cell adhesion are
altered, and future study will determine whether these alterations play a role in regulating
proliferation. Cadherin-13 is of particular interest because of its anti-adhesive properties and
the fact that its expression correlates with SMC proliferation (209). Another potential gene
for follow-up is caveolin-1, which was upregulated 1.96-fold in Acta2-/- SMCs.
Phosphorylated caveolin-1 is necessary but not sufficient to stabilize FAK within FAs and
promote FA turnover (210). A third gene that deserves further study is Pip5k1b. The
observation of increased Pip5k1b expression in the Acta2-/- SMCs raises the question of
whether Pip2 production is altered at FAs in these cells. Although the α and β isoforms of
Pip5k1 are not directly associated with FAs, the γ isoform is, and all of the Pip5k1 isoforms
are responsible for some of the Pip2 production within the cell. Pip2 promotes the nucleation
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of new actin filaments by causing the release of gelsolin from actin (211). Pip2 also plays a
role in FAK activation; however, localization within the cell is important. It remains to be
determined whether Pip5k1b protein levels are increased, and whether increased Pip2
production within the cytoplasm plays a role in FA signaling in the Acta2-/- SMCs. A fourth
adhesion-related gene, Srpx2 (Sushi repeat containing protein, X-linked 2), may be
interesting for follow-up as well. As previously mentioned, this protein is capable of
activating FAK and promoting cell adhesion and migration in gastric cancer (200). All of
these genes have potential relevance to both FAK and cell proliferation, and support a role
for FAK regulation of proliferation in Acta2-/- SMCs. Future work will elucidate the role of
these genes in Acta2-/- SMC proliferation.
In these studies, we have described for the first time alterations in both FA gene
expression and protein localization in Acta2-/- SMCs, along with a role for FAK in driving
increased proliferation in these cells. Since SM α-actin stabilizes FAs to allow for generation
of contractile force, an inability to form SM α-actin filaments could result in increased FAKmediated turnover of FAs and/or inability of the cells to form fully mature FAs capable of
transducing mechanical force and responding to mechanical stress. Our data showing altered
vinculin, zyxin, and phospho-FAK localization supports the idea that the Acta2-/- SMCs are
unable to generate sufficient tension. The fact that FAK inhibitors reduced proliferation in
Acta2-/- SMCs to levels equal to wildtype SMCs suggests a role for FAK signaling in driving
Acta2-/- SMC proliferation. Thus, the altered FAK localization and signaling may be a
compensatory mechanism resulting from the inability of Acta2-/- SMCs to generate sufficient
intracellular tension.
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Our data suggest Acta2-/- SMCs have decreased ability to respond to mechanical
stress; therefore, stretching the SMCs in vitro may reveal even more pronounced alterations
in FAs. Future studies will determine whether this is the case, by exposing the cells to
cyclic mechanical strain on a Flexcell apparatus. Additionally, the specific downstream
pathways activated by FAK to induce proliferation in Acta2-/- SMCs remain undefined, and
future work will determine whether a specific downstream pathway or a combination of
pathways are driving proliferation. Based on our current data, we predict that multiple
pathways are likely to contribute.
In addition to these in vitro studies, we also plan to determine SMC proliferation in
vivo in the Acta2-/- mice is dependent on FAK, using an established carotid injury model.
Data generated using this model show that Acta2-/- mice have a greater proliferative response
to vascular injury than wildtype mice, and we expect that a FAK inhibitor will prevent this
proliferation in vivo. Finally, it will be exciting to determine whether FA alterations and
FAK signaling are altered in patients heterozygous for ACTA2 or MYH11 mutations.
Disruption of an SMC-specific contractile protein leading to an increase in FAK-dependent
proliferation may represent a novel pathway leading to the combined phenotype of familial
TAAD and vascular occlusive disease.
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CHAPTER VI
DISCUSSION
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We have identified a novel vascular pathology caused by mutations in the SMCspecific contractile genes MYH11 and ACTA2. These studies provide the pathologic and cell
biology data to support the hypothesis that a single gene defect can cause diverse vascular
diseases in multiple arteries throughout the body. Furthermore, our data suggest two
differing effects of ACTA2 mutations on SMCs: a loss of function, leading to decreased
SMC contraction, and a gain of function, leading to increased SMC proliferation (Figure
VI-1).

Figure VI-1. A model for disease pathogenesis due to loss of SM α-actin filaments.
**************************************************************************
Loss of Contractile Function Resulting From MYH11 and ACTA2 Mutations.
Multiple lines of evidence support a loss of contractile function in ACTA2/MYH11
aortas. All of the currently identified mutations in MYH11 and ACTA2 are predicted to
disrupt the structure and/or function of the protein. Mutations in MYH11 located in the
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ATPase domain are predicted to impair ATPase activity, and mutations in the coiled-coil
domain are predicted to disrupt the structure (36). Mutations in ACTA2 are predicted to
adversely affect actin polymerization and interaction with other proteins (34). Patients with
MYH11 mutations showed a decrease in aortic compliance (86). Mice deficient in either
Acta2 or Myh11 have decreased contractility of arterial segments, supporting that loss of
either of these contractile protein leads to decreased SMC contractility. Our data show that
SMCs explanted from both patients with ACTA2 and MYH11 mutations failed to form SM
α-actin filaments, the thin filaments required for contractile function. Loss of SM α-actin
results in decreased aortic contractility in the Acta2-/- mouse, demonstrating that SM α-actin
is required for maximal force generation by SMCs (117). Therefore, the disruption in
contractile filament structure is highly likely to result in decreased contractile function.
In addition to the histologic data in patients’ SMCs and myofibroblasts, our study of
FAs in Acta2-/- mouse SMCs also support the notion that the decreased contractility due to
loss of SM α-actin filaments disrupts FAs and actin filament associated proteins in SMCs.
Immunofluorescent labeling of vinculin, a marker for FAs, showed a marked reduction in
FAs, with the remaining FAs located mainly at the cell periphery in Acta2-/- SMCs. The
amount of vinculin localized in FAs correlates with the amount of contractile force being
generated across FAs by SMCs, and vinculin localization to FAs is necessary in order to
transmit this contractile force (207). Therefore, the disruption in vinculin likely indicates a
loss of contractile function in the Acta2-/- SMCs. Actin thin filaments are anchored to the
cell at integrin-containing FAs in SMCs (60). Since integrin signaling at FAs allows for
communication with the ECM and transduction of mechanical force between the cell and the
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ECM, a disruption in one component of this mechanism is likely to disrupt the development
of mechanical force by the SMC (178).
Data from these studies strengthen a growing body of evidence that one of the
primary underlying defects in TAAD pathogenesis is the disruption of the structure and/or
function of the SMC contractile unit (12). This disruption leads to an impairment of cellmatrix communication, and secondarily may lead to secretion of cytokines and growth
factors, as well as release of latent factors from the ECM. Interestingly, a similar
pathogenesis has been suggested for mutations in cardiac contractile protein mutations that
lead to hypertrophic cardiomyopathy (96). Our data showing the upregulation of IGF-1
transcript levels in patients with ACTA2 and MYH11 mutations suggest that the SMCs are
compensating for a loss of contractile function by increasing production of this particular
growth factor, which is known to drive the expression of contractile proteins in SMCs
Additional studies from our lab and from others support this hypothesis. Other
factors that lead to increased pressures on aortic SMC contractile units, such as hypertension
or heavy weightlifting, lead to ascending aortic aneurysm formation. This overload of SMCs
may induce activation of SMC pathways in a similar manner to pathways induced due to
defects in SMC contraction due to mutations in contractile proteins. In addition, other
mutant genes identified to predispose to thoracic aortic disease may also lead to decreased
contractile function of SMCs. Experimental evidence suggests that SMCs from TGFBR2
mutant individuals fail to maintain a differentiated, contractile phenotype (Inamoto et al.,
manuscript submitted). Mutations in MLCK disrupt kinase activity of the enzyme,
suggesting disruption in SMC contractility (Wang et al., manuscript submitted). Even in
cases of FBN1 mutations, where TGF-β1 has been shown to play a role in disease

133

pathogenesis, the mutations are also likely to disrupt contractile function. As mentioned
previously, fibrillin-1 binds to αvβ3, α5β1, and αvβ6 integrins on the surface of SMCs, and
fibrillin-1 containing microfibrils form an essential part of the connections between SMCs
and elastic fibers (11;13). Missense mutations in FBN1 disrupt formation of these
microfibrils, leading to decreased microfibrils in the vessel wall (12). Therefore, FBN1
mutations may also perturb the SMC mechanotransduction complex and lead to decreased
contractility. In mice that underexpress fibrillin-1, one of the early pathologic abnormalites
noted was a smooth appearance of elastic fibers, suggestive of a loss of connectivity
between the ECM and SMCs (22). Decreased contractility has also been reported in the
aortas of MFS mice harboring a heterozygous missense mutation in fibrillin-1, due to loss of
elastic fibers and increased matrix metalloprotease activity (24). This is consistent with the
idea that any disruption in the connections between SMC contractile filaments, focal
adhesions, and the ECM ultimately result in a decrease in contractility.

Gain of Proliferative Function
Our data also indicate a gain of proliferative function in smaller arteries, which has
been a major focus of this work. Histologic and clinical data from patients heterozygous for
either ACTA2 or MYH11 mutations, as well as data from Acta2-/- mice, suggest that SMC
hyperproliferation occurs associated with ACTA2 mutations, both in vitro and in vivo.
Histologic data show focal areas of increased SMCs in the aortic media of ACTA2 and
MYH11 patients. Additionally, thickening of the medial layer of the arteries in the vasa
vasorum due to increased SMCs was noted, leading to stenosis or occlusion of these arteries.
Abnormal thickening of epicardial arteries, and luminal narrowing or a coronary artery due
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to fibrocellular intimal plaque formation was observed. Clinical data also indicate that
excessive SMC proliferation may be occurring. Individuals harboring ACTA2 mutations
have increased likelihood of developing CAD, stroke, or Moyamoya disease, in the absence
of other cardiovascular risk factors including hypertension, smoking, and
hypercholesterolemia. An individual heterozygous for a recently identified de novo ACTA2
mutation, R179C, was found to have aortic coarctation, a narrowing of the aorta resulting
from hyperproliferation of SMCs (Dianna Milewicz, personal communication) (212). Other
individuals with the same de novo mutation had primary pulmonary hypertension, which
was diagnosed based on SMC proliferative lesions in the pulmonary vasculature (Dianna
Milewicz, personal communication). Data indicating medial thickening in Acta2-/- mouse
aortas suggest that SMC proliferation is occurring in vivo in these mice due to total loss of
SM α-actin. Future study will determine whether this proliferation is occurring before or
during expansion of the vessel wall. In addition, more excessive SMC proliferation leading
to significant stenoses of arteries was found with arterial injury in the Acta2-/- mouse when
compared with wildtype mice (Dianna Milewicz, personal communication).
SMCs and myofibroblasts expressing SM α-actin from ACTA2 mutant individuals
displayed a significant increase in proliferation in vitro compared with controls. Complete
loss of Acta2 leads to increased SMC proliferation as well as migration in vitro, consistent
with published data from Acta2-/- kidney myofibroblasts (124). Further investigation
revealed a role for FAs, and specifically a role for excessive activation of FAK signaling, in
mediating proliferation in Acta2-/- SMCs. Treatment of Acta2-/- SMCs with two different
FAK inhibitors completely blocked increased proliferation when the cells were plated on
fibronectin-1, suggesting a role for FAK in Acta2-/- SMC proliferation.
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Focal Adhesion Dependent Regulation of Proliferation in Acta2-/- SMCs
We are proposing a novel vascular disease mechanism in which disruption of a
SMC-specific contractile protein leads to SMC hyperplasia through altered signaling at focal
adhesions, and propose this increased proliferation can lead to occlusive vascular lesions.
SM α-actin stabilizes FAs in myofibroblasts (181). In our model of disease progression, loss
of SM α-actin filaments would lead to destabilization of FA complexes, resulting in
localization of FA complexes mainly at the cell periphery. Consistent with this notion,
vinculin was localized mainly at the cell periphery in Acta2-/- SMCs. We also observed
increased phosphorylated FAK localization at the cell periphery. Since FAK activation in
part drives SM α-actin expression in response to external forces on the cell, it is possible that
increased phosphorylated FAK at the cell periphery is a compensatory response due to loss
of SM α-actin in the Acta2-/- mice (183). Activated FAK facilitates FA turnover, and also
leads to activation of multiple cellular pathways capable of driving increased proliferation,
including ERK, PI3K/Akt, Rho/ROCK, and Rac/JNK (67;68;184;185). Therefore, we
propose that loss of Acta2 leads to a destabilization of FAs and subsequent increase in FAK
signaling, and that FAK activates multiple cellular pathways to drive proliferation (Figure
VI-2).
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Figure VI-2. Pathways downstream of FAK potentially driving increased proliferation in
Acta2-/- SMCs compared with wildtype SMCs.
**************************************************************************
Inhibitor assays using two different FAK inhibitors reversed the increased proliferation in
Acta2-/- SMCs to levels similar to wildtype cells, suggesting that Acta2-/- SMCs proliferate
in a FAK-dependent manner. Further, this FAK-dependent proliferation may be driving
occlusive vascular lesions in response to injury. Data obtained in our lab show that
neointimal formation is increased following carotid artery ligation in Acta2-/- mice compared
with wildtype. Additionally, other models of carotid injury-induced proliferation are
connected with FA regulation. Balloon injury of rat carotid arteries leads to decreased
expression of integrin-linked kinase and disruption of FA formation (73). These data are
consistent with another report that deletion of integrin-linked kinase (ILK), another FAassociated kinase, disrupts FA maturation (201). Together, these data provide support for a
novel pathway in which Acta2 deficiency leads to increased proliferation through disruption
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of FAs and subsequent increases in FAK-dependent signaling. Future work will determine
which specific pathways downstream of FAK are driving the increased proliferation.

Parallels With NF1 Vasculopathy
The diffuse vasculopathy found in ACTA2 patients bears similarities to the
vasculopathy found in patients with Neurofibromatosis type I (NF1), an autosomal dominant
disorder that results in effects on mainly the nervous system, but also the vascular system as
well. NF1 has been shown to lead to stenosis or occlusion of arteries, and less commonly, to
aneurysm formation. Both ACTA2 mutations and NF1 can also lead to occlusive disease in
multiple vascular beds, and this spectrum of occlusive disease includes aortic coarctation,
and also Moyamoya disease (213). The human NF1 gene, encoding neurofibromin,
functions as a negative regulator of Ras signaling in SMCs, suggesting a link between NF1
mutations and the SMC hyperplasia leading to vessel stenosis and occlusion (214).
Nf1 deficient mice display increased responsiveness to vascular injury compared to
their wildtype counterparts. Mice with heterozygous for a deletion in the Nf1 gene display
increased neointimal formation after vascular injury (72). This proliferation can be inhibited
both by blocking Ras-mediated signaling and through treatment of the mice with Gleevec, a
pharmacological inhibitor of Ras (72;215). The proliferative response to injury in Acta2-/mice parallels the response to carotid injury observed in Nf1 deficient mice. Interestingly,
neurofibromin, the protein encoded by Nf1, was recently found to interact directly with FAK
(216). Nf1-/- MEF cells are more elongated, and FAK is redistributed to the cell periphery,
specifically at the leading edge of the cells (216). Together, these data, along with our data
from Acta2-/- mice, support the notion that disruptions in a single gene can lead to occlusive

138

disease in multiple vascular beds. Further, these studies implicate SMC proliferation in the
formation of these occlusive diseases and further support our hypothesis that disruptions in
FAs lead to a proliferative vascular response to injury.

Future Research Directions
Future work will focus both on mouse models of ACTA2 and MYH11 mutations and
confirmation of results in human tissue and cell samples. Plans for the immediate future
include further characterization of the Acta2-/- mouse model, as well as development of
transgenic and knock-in mice that carry the R258C mutation, one of the more severe
mutations in ACTA2. Mice will be imaged using MRA, as well as echocardiography, to
confirm aneurysm formation and determine the earliest age of onset of disease. Pathological
study of these mice should provide further insight into the major mechanisms driving
aneurysm formation due to SMC contractile mutations. Mouse models will aid in
elucidating the specific role of FAs and FAK in increased proliferation leading to the
occlusive lesions in vivo. Acta2-/- mice display increased neointimal formation post carotid
artery ligation: future work will determine 1) whether this holds true in transgenic and
knock-in mouse models and 2) whether this increase can be blocked through treatment of
mice with a FAK inhibitor.
The mouse models will also aid in determining whether increased proliferation plays
a role in aneurysm formation, and whether this proliferation is FAK-dependent. Some
experimental evidence exists to suggest a role for increased cell proliferation in aneurysm
formation. The observation of focal areas of increased SMCs in ACTA2 and MYH11 aortic
tissues supports this idea. Also, LDLR-related protein (LRP) deficient mice develop
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aneurysms with medial thickening, atherosclerosis, and SMC hyperplasia (217). Another
group reported medial thickening and sustained SMC density in TAA, implying that SMCs
proliferated to maintain the same density as the aortic wall expanded (82). It is interesting to
note that aneurysm formation is evident in Acta2-/- mice with only minimal changes typical
of medial degeneration (increased proteoglycans and elastic fiber degradation). The only
pathologic abnormality noted is increased SMCs in the aortic medial layer. This observation
raises the possibility that excessive SMC proliferation may contribute to aneurysm
formation. Furthermore, we are interested in determining if blocking this proliferation will
prevent aneurysm formation. Once a role for FAK inhibitors in preventing neointimal
proliferation in response to carotid ligation has been established, mice will be treated with
FAK inhibitors prior to the onset of TAA formation. MRA and histologic studies will be
used to determine whether FAK inhibition prevents aneurysm formation and associated
medial degeneration.
Further work is needed to better quantify and characterize the specific alterations in
FAs in Acta2-/- mice as well as in human samples. Our studies of Acta2-/- mice showed
alterations in vinculin as well as zyxin. Total internal reflection fluorescence (TIRF)
microscopy will be used to quantify the amounts of these and other FA proteins, including
FAK and tensin, localized specifically on the cell membrane. Additionally, the results
showing alterations in zyxin localization require follow-up to 1) confirm the results are bona
fide and 2) determine the specific subcellular structure(s) that zyxin is localized to in the
Acta2-/- SMCs.
We also plan to determine whether FAs are altered in human myofibroblast and
SMC samples from TAAD patients. Initial study will focus on samples harboring ACTA2 or
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MYH11 mutations, and will later be expanded to determine whether alterations in FAs are
commonly disrupted in TAAD. There is a possibility that other TAAD mutations lead to a
common disruption of FA formation and/or maturation. Data from our lab showing that
MYLK mutations disrupt myosin light chain kinase function in SMCs, together with another
study showing that myosin light chain kinase inhibitors prevent FA maturation, support this
idea (Wang et al., manuscript submitted) (218).
Another issue to pursue using the mouse models is the question of whether TGF-β1
signaling contributes to the pathogenesis of aneurysms caused by contractile mutations.
While our initial data from human subjects does not indicate that increased TGF-β1
signaling is present, we currently cannot completely rule out the possibility of TGF-β1
involvement in pathogenesis. We have proposed that the major underlying defect in these
patients, and the initial insult that leads to disease progression, is the defective ability of
SMCs to contract properly, resulting in alterations in focal adhesion maturation and/or
stability. However, TGF-β1 may still play a role in disease pathogenesis. Treatments that
have been utilized in preventing aneurysm formation in mouse models of MFS such as TGFβ1 neutralizing antibodies, Doxycycline, or Losartan should provide insight into 1) whether

TGF-β1 is contributing to pathogenesis in the Acta2-/- and transgenic and knock-in mouse
models, and 2) whether similar treatments under development for treating MFS would also
be beneficial for treating familial TAAD patients, particularly those with mutations in
MYH11/ACTA2.
Since we observed increases in IGF-1 in ACTA2 and MYH11 patients, it is
particularly interesting to note that the IGF-1 receptor and FAK interact in SMCs as well as
other cell types. The IGF-1 receptor stimulates FAK phosphorylation in SMCs (219).
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Conversely, FAK activates the IGF-1 receptor independently of IGF-1R
autophosphorylation and also stabilizes the expression of the receptor (220). In human
pancreatic adenocarcinoma cells, multiple combinations of FAK and IGF-1R inhibitors
synergistically blocked cell proliferation, whereas proliferation was not inhibited with use of
either FAK inhibitors or IGF-1R inhibitors alone (221). In our studies, an IGF-1R inhibitor
failed to prevent increased proliferation in ACTA2 mutant myofibroblasts. It is possible that
either a FAK inhibitor alone, or dual inhibition using lower doses of both FAK and IGF-1R
inhibitors may completely prevent ACTA2 mutant myofibroblast proliferation.
In conclusion, the data gained from this study provide support for the existence of a
hyperplastic vasculomyopathy leading to diffuse and diverse vascular diseases in the
absence of other cardiovascular risk factors including hyperlipidemia, smoking, and
hypertension. Further, the ideas of 1) FAK dependent mechanism of SMC hyperproliferation
and 2) a role for SMC proliferation in aneurysm formation suggest that FAK inhibition may
be a viable treatment option in the future for TAAD associated with early-onset vascular
occlusive diseases.
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